[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 317
1. Rosa MI, Medeiros LR, Rosa DD, Bozzeti MC, Silva FR, Silva BR: [Human papillomavirus and cervical neoplasia]. Cad Saude Publica; 2009 May;25(5):953-64
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human papillomavirus and cervical neoplasia].
  • [Transliterated title] Papilomavírus humano e neoplasia cervical.
  • Human papillomavirus (HPV) has been established as an important etiological factor for the development of cervical cancer.
  • This DNA virus primarily infects the epithelium and can induce benign and malignant lesions of the mucous membranes and skin.
  • Some HPVs are considered high risk due to their role in malignant progression of cervical tumors.
  • Only a small fraction of infected women develop cervical cancer, implying the involvement of environmental and genetic cofactors in cervical carcinogenesis.
  • Classification, virology, pathology, natural history, epidemiological features of genital HPV infection, and future prospects for cervical cancer prevention with HPV vaccines will be reviewed here.
  • [MeSH-major] Papillomaviridae / classification. Papillomavirus Infections / virology. Tumor Virus Infections / virology. Uterine Cervical Neoplasms / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19488480.001).
  • [ISSN] 1678-4464
  • [Journal-full-title] Cadernos de saúde pública
  • [ISO-abbreviation] Cad Saude Publica
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 112
  •  go-up   go-down


2. Sun JJ, Wang ZY, Xie JC, Li ZD, Ma CC, Liu B, Zhao JZ: [Comparative analysis between multi-segments intramedullary spinal cord congenital tumors and benign ependymomas]. Beijing Da Xue Xue Bao; 2010 Apr 18;42(2):183-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative analysis between multi-segments intramedullary spinal cord congenital tumors and benign ependymomas].
  • OBJECTIVE: To comparatively analyze the different and common points between multi-segments intramedullary spinal cord congenital tumors and benign ependymomas, such as the patient's age, gender, nervous functions and tumor location, longitudinal extension, and removed extent.
  • METHODS: Data were studied from 12 patients with multi-segments intramedullary spinal cord congenital tumors and 19 patients with multi-segments intramedullary spinal cord benign ependymomas who underwent microsurgery for the tumor using a posterior approach.
  • The tumor was exposed through dorsal myelotomy.
  • Independent sample t-test was performed for ages, preoperative IJOA scores, postoperative IJOA scores and IJOA difference values of the patients, and longitudinal extension of tumors in the two groups with congenital tumors and benign ependymomas.
  • Two independent sample Mann-Whitney tests was performed for the patient's gender, stool and urine functions, limbs weakness, and tumor removed extent in the two groups.
  • RESULTS: The average age of patients in congenital tumors group was 23.5+/-14.3, and in benign ependymomas group was 37.8+/-12.9, the age difference between the two groups was statistically significant (t=-2.89, P=0.007).
  • 78.9 (15/19) percent of multi-segments intramedullary spinal cord benign ependymomas were located at the cervical and cervicothoracic segments.
  • Total or nearly total resection was achieved in 94.7% (18/19) patients with benign ependymomas.
  • CONCLUSION: It is known from the clinical files that most multi-segments intramedullary spinal cord congenital tumors are found in young patients and most benign ependymomas in the middle-aged.
  • Most benign ependymomas are located at the cervical and cervicothoracic segments, and they are easy to totally remove.
  • [MeSH-major] Ependymoma / surgery. Spinal Cord Neoplasms / congenital. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Magnetic Resonance Imaging. Male. Microsurgery / methods. Neurosurgical Procedures / methods. Teratoma / congenital. Teratoma / diagnosis. Teratoma / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396361.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Soto G S, Valdés E F, Krämer Sch A, Mariné M L, Bergoeing R M, Mertens M R, Solar G A, Walton D A, Vergara G J: [Carotid body tumors: report of ten cases]. Rev Med Chil; 2007 Nov;135(11):1414-20
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumor del cuerpo carotídeo: A propósito de 10 casos tratados.
  • PATIENTS AND METHODS: Between 1984 and 2006, we operated 8 women and 2 men, aged 19 to 75 years, with this type of tumor.
  • RESULTS: The most common cause for consultation was a cervical mass in 90%, with a mean evolution lapse of 13.2 months (range 3 to 126).
  • In all cases, diagnosis was confirmed with angiographic imaging and histopathology.
  • These infrequent lesions are generally benign, early surgical removal by surgeons with vascular expertise avoids neurological and or vascular complications.
  • [MeSH-major] Carotid Body Tumor. Paraganglioma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259652.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 25
  •  go-up   go-down


Advertisement
4. Falavigna A, Righesso O, Volquind D, Teles AR: Intramuscular myxoma of the cervical paraspinal muscle. Eur Spine J; 2009 Jul;18 Suppl 2:245-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramuscular myxoma of the cervical paraspinal muscle.
  • Myxoma is a neoplasm of mesenchymal origin composed of undifferentiated stellate cells in a myxoid stroma.
  • This tumor can develop in a variety of locations.
  • Only ten cases of these benign tumors involving the neck muscles were reported in literature.
  • A 64-year-old woman presented with occipital and neck pain over 5 years noted an expansive painful lesion located at posterior cervical region with progressive volume increase in the last 12 months.
  • Tumor total removal was performed through normal muscle margins and the vertebral periosteum was scraped.
  • The tumor was encapsulated, lobulated with a gray-white appearance.
  • The histological examination yielded the diagnosis of intramuscular myxoma.
  • In conclusion, although rare, intramuscular myxoma should be included in differential diagnosis of cervical paraspinal tumors.
  • Despite its benign characteristics, local recurrence was reported after subtotal resection.
  • Tumor total removal should be the goal of surgery.
  • [MeSH-major] Cervical Vertebrae. Muscle Neoplasms / diagnosis. Muscle, Skeletal. Myxoma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Diagn Pathol. 2000 Apr;4(2):99-123 [10760324.001]
  • [Cites] Ann Surg. 1948 May;127(4):706-19 [18917127.001]
  • [Cites] Pediatr Radiol. 2002 Feb;32(2):120-2 [11819080.001]
  • [Cites] Auris Nasus Larynx. 2004 Sep;31(3):319-22 [15364372.001]
  • [Cites] Br J Surg. 1973 Feb;60(2):122-4 [4265487.001]
  • [Cites] Arch Otolaryngol. 1976 May;102(5):300-5 [1267724.001]
  • [Cites] Cancer. 1979 Feb;43(2):512-25 [421179.001]
  • [Cites] Am J Clin Pathol. 1985 Sep;84(3):265-72 [4036856.001]
  • [Cites] Arch Otolaryngol. 1985 Oct;111(10):699-701 [4038143.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):740-7 [3524794.001]
  • [Cites] Laryngoscope. 1987 Jan;97(1):105-7 [3796168.001]
  • [Cites] Nutr Rev. 1989 Jan;47(1):23-5 [2649802.001]
  • [Cites] Br J Radiol. 1992 Jun;65(774):485-90 [1628179.001]
  • [Cites] Dermatol Surg. 1995 Mar;21(3):251-4 [7712099.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1222-7 [9777984.001]
  • [Cites] Am J Clin Pathol. 1965 Feb;43:104-13 [14253111.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Apr;133(4):398-401 [17438256.001]
  • [Cites] Am J Otolaryngol. 2000 May-Jun;21(3):184-9 [10834553.001]
  • (PMID = 19301043.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  • [Other-IDs] NLM/ PMC2899565
  •  go-up   go-down


5. Pinto DC, Vidigal Tde A, Castro Bd, Santos BH, ousa NJ: Rosai-Dorfman disease in the differential diagnosis of cervical lymphadenopathy. Braz J Otorhinolaryngol; 2008 Jul-Aug;74(4):632-5
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rosai-Dorfman disease in the differential diagnosis of cervical lymphadenopathy.
  • Rosai-Dorfman Disease or Sinus Histiocytosis with Massive Lymphadenopathy (SHML) is a rare benign disease of unknown etiology, which presents with cervical lymphadenopathy.
  • The authors describe one case of a 43-year-old man with bilateral cervical masses, nasal obstruction, fever, weight loss and decreased vision with 6 months duration.
  • As his social history was positive for tobacco and alcohol use, the initial diagnosis was a possible rhinopharyngeal malignant tumor.
  • Medical investigation established the diagnosis of SHML.
  • After therapy, the 6-month follow-up evidenced the patient's clinical improvement, although cervical masses persisted.
  • [MeSH-major] Histiocytosis, Sinus / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Glucocorticoids / therapeutic use. Humans. Lymphatic Diseases / diagnosis. Male. Neck. Prednisone / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Rosai-Dorfman disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852995.001).
  • [ISSN] 1808-8694
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


6. Munro EG, Jain M, Oliva E, Kamal N, Lele SM, Lynch MP, Guo L, Fu K, Sharma P, Remmenga S, Growdon WB, Davis JS, Rueda BR, Batra SK: Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance. Int J Gynecol Pathol; 2009 Mar;28(2):127-33
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance.
  • MUC4 is a transmembrane glycoprotein more highly expressed in cervical dysplasia than benign cervical epithelium.
  • We sought to determine whether MUC4 expression differs between benign and malignant cervical tissue.
  • Fifty-eight patients with benign, dysplastic, or malignant cervical pathology were identified retrospectively, and representative sections were stained with a mouse monoclonal anti-MUC4 antibody.
  • Semiquantitative analysis was performed on benign, dysplastic, and malignant regions by scoring staining intensity (0: negative, 1: weak, 2: moderate, and 3: strong) and distribution (focal <10%, multifocal=10%-60%, diffuse > or =60%).
  • In samples with benign glycogenated squamous epithelium, only the parabasal cells had MUC4 staining, and 48.5% had an intensity of 2 or 3.
  • Cervical intraepithelial neoplasia (CIN) 1 samples had variable staining with an intensity similar to glycogenated squamous epithelium but distribution similar to squamous metaplasia.
  • In contrast, no differences in staining were observed between benign endocervical glands, adenocarcinoma in situ, and invasive adenocarcinoma.
  • These expression patterns suggest that MUC4 is a lineage marker in benign cervical tissue that may have aberrant expression in squamous dysplasia and carcinoma.
  • Further studies may elucidate the role of MUC4 in the development of squamous cell cervical cancer.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4033-40 [11751498.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncogene. 2002 Oct 24;21(49):7524-32 [12386815.001]
  • [Cites] Bioessays. 2003 Jan;25(1):66-71 [12508284.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):13-7 [14668544.001]
  • [Cites] Gut. 2000 Dec;47(6):753-61 [11076872.001]
  • [Cites] Front Biosci. 2001 Oct 1;6:D1192-206 [11578969.001]
  • [Cites] Hum Pathol. 2001 Nov;32(11):1197-202 [11727258.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):849-55 [14675323.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):622-30 [14744777.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):209-14 [15047238.001]
  • [Cites] Cancer Res. 1994 Feb 1;54(3):637-9 [7905784.001]
  • [Cites] Hum Reprod. 1995 Jan;10(1):98-102 [7745080.001]
  • [Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]
  • [Cites] Biol Reprod. 1997 Apr;56(4):999-1011 [9096884.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5263-6 [10026131.001]
  • [Cites] Biochem J. 1999 Mar 1;338 ( Pt 2):325-33 [10024507.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):354-8 [10366459.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Front Biosci. 2006;11:2071-6 [16720293.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1510-5 [17090193.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Cancer Lett. 2007 Jun 28;251(2):247-57 [17210225.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):791-6 [12090430.001]
  • (PMID = 19188823.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA078590-13; United States / NCI NIH HHS / CA / CA78590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4
  • [Other-IDs] NLM/ NIHMS228381; NLM/ PMC2932462
  •  go-up   go-down


7. Gerszten PC, Burton SA, Ozhasoglu C, McCue KJ, Quinn AE: Radiosurgery for benign intradural spinal tumors. Neurosurgery; 2008 Apr;62(4):887-95; discussion 895-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for benign intradural spinal tumors.
  • OBJECTIVE: The role of stereotactic radiosurgery for the treatment of intracranial benign tumors is well established.
  • There is less experience and more controversy regarding its use for benign tumors of the spine.
  • This study evaluated the clinical efficacy of radiosurgery as part of the treatment paradigm of selected benign tumors of the spine.
  • METHODS: Seventy-three benign intradural extramedullary spinal tumors were treated with a radiosurgery technique and prospectively evaluated.
  • Lesion location included 43 cervical, five thoracic, 19 lumbar, and six sacral.
  • Tumor histology included neurofibroma (25 cases), schwannoma (35 cases), and meningioma (13 cases).
  • Tumor volume ranged from 0.3 to 93.4 cm (mean, 10.5 cm; median, 4.11 cm).
  • Radiosurgery was used for the treatment of postsurgical radiographic progression in 18 cases; it was used as the primary treatment modality in 14 cases; it was used for treatment of radiographic tumor progression in nine cases; and it was used for the treatment of postsurgical residual tumor in two cases.
  • Long-term radiographic tumor control was demonstrated in all cases.
  • CONCLUSION: Single fraction radiosurgery was found to be clinically effective for the treatment of benign extramedullary spinal neoplasms.
  • Although surgical extirpation remains the primary treatment option for most benign spinal tumors, radiosurgery was demonstrated to have short-term clinical benefits for the treatment of such lesions.
  • [MeSH-major] Radiosurgery / methods. Spinal Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496194.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Zhou YA, Huang JH, Wan CY, Zuo ZB: [Surgical treatment and effect observation of cervical intraspinal benign neoplasms]. Zhongguo Gu Shang; 2009 Nov;22(11):856-8
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment and effect observation of cervical intraspinal benign neoplasms].
  • OBJECTIVE: To investigate the diagnosis, surgical procedure and clinical outcome of cervical intraspinal benign neoplasm.
  • Cervical stability in 11 cases was restored after removal of tumors.
  • The average recover ratio of total was (46.7 +/- 2.46)%, cervical stability was (62.37 +/- 3.58)%, the other methods was (41.21 +/- 4.63)%.
  • CONCLUSION: The surgical exairesis for cervical intraspinal benign neoplasm has low post-operative recurrence.
  • The main reason of recurrence is not removed the tumor completely.
  • MRI is regarded the effective method which is helpful in differential diagnosis and surgery guidance.
  • [MeSH-major] Cervical Vertebrae / pathology. Cervical Vertebrae / surgery. Spinal Neoplasms / pathology. Spinal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084949.001).
  • [ISSN] 1003-0034
  • [Journal-full-title] Zhongguo gu shang = China journal of orthopaedics and traumatology
  • [ISO-abbreviation] Zhongguo Gu Shang
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Sahdev A: Cervical tumors. Semin Ultrasound CT MR; 2010 Oct;31(5):399-413
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical tumors.
  • Imaging the cervix for benign and malignant disease can be achieved using transvaginal ultrasound, computed tomography (CT), magnetic resonance imaging, and 18-fluorodeoxyglucose positron emission tomography.
  • The best established role of imaging is in cervical carcinoma where magnetic resonance imaging, CT and increasingly positron emission tomography-CT are the most frequently used imaging modalities.
  • Histopathological diagnosis of cervical disorders cannot be made on the basis of imaging alone but certain imaging features may provide an indication as to the underlying diagnosis.
  • We describe the imaging features of some malignant tumor subtypes in which a preoperative diagnosis may alter management.
  • Benign lesions of the cervix are usually detected incidentally or during investigations for dysfunctional vaginal bleeding.
  • We describe the imaging features of the commonly encountered benign cervical lesions.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Cervix Uteri / pathology. Cervix Uteri / radiography. Cervix Uteri / radionuclide imaging. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Neoplasm Staging. Radiopharmaceuticals. Radiotherapy Planning, Computer-Assisted / methods. Uterine Cervical Diseases / diagnosis


10. Tosun G, Sendag F, Zeybek B, Cosan Terek M, Guven C, Zekiogly O, Bilgin O: Immunohistochemical expressions of p16 and p53 proteins in cervical intraepithelial neoplasia and in benign cervical tissue. Eur J Gynaecol Oncol; 2010;31(6):627-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expressions of p16 and p53 proteins in cervical intraepithelial neoplasia and in benign cervical tissue.
  • PURPOSE OF INVESTIGATION: To evaluate the immunohistochemical expressions of p16 and p53 in cervical intraepithelial neoplasia (CIN) and do a comparison with non-neoplastic cervical lesions.
  • CONCLUSION: While p16 is useful in detecting high-grade cervical lesions, p53 is not a good biomarker for distinguishing high-grade lesions from low grade ones.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervical Intraepithelial Neoplasia / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Papillomavirus Infections / metabolism. Tumor Suppressor Protein p53 / metabolism. Uterine Cervical Neoplasms / metabolism

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319504.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


11. Zou JF, Li JY, Wu XW, Chen SY: [Effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Dec;26(12):1252-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic].
  • AIM: To investigate the effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic.
  • METHODS: 120 patients with ovarian benign tumor treated by laparoscopic therapeutic were randomly divided into two groups with 60 cases each.In group A, patients received general anesthesia eombined with thoracic epidural anesthesia during surgery, patients in group B received general anesthesia.
  • The cervical venous blood samples were obtained at the following time points: before induction of anesthesia(T0), 30 min after anesthesia (T1), 1 h during operation (T2), 24 h after operation (T3), 48 h after operation (T4) and 72 h after operation (T5).RRCR, RRICR and RTRR were measured at different time points.
  • CONCLUSION: Anesthesia may harm on erythroeyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic.
  • [MeSH-major] Analgesia / adverse effects. Anesthesia / adverse effects. Erythrocytes / immunology. Laparoscopy. Ovarian Neoplasms / immunology. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Anesthesia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21138693.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  •  go-up   go-down


12. Lee JW, Choi JJ, Lee KM, Choi CH, Kim TJ, Lee JH, Kim BG, Ahn G, Song SY, Bae DS: eIF-4E expression is associated with histopathologic grades in cervical neoplasia. Hum Pathol; 2005 Nov;36(11):1197-203
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] eIF-4E expression is associated with histopathologic grades in cervical neoplasia.
  • The expression is known to be elevated in several carcinomas as compared with normal tissues and benign lesions.
  • In the present study, we undertook to determine whether eIF-4E expression is associated with progression in cervical neoplasia. eIF-4E expression was evaluated by immunohistochemistry in 88 formalin-fixed, paraffin-embedded cervical tissues; 10 normal cervical specimens; 19 low-grade cervical intraepithelial neoplasias (CINs); 19 high-grade CINs; and 40 invasive squamous cell carcinomas (ISCCs).
  • In addition, eIF-4E expression was evaluated at the RNA level in fresh frozen cervical carcinoma tissues by real-time quantitative reverse transcriptase polymerase chain reaction.
  • Immunohistochemical staining showed that eIF-4E expression was undetectable in most normal cervical squamous epithelial tissues (90%), but variable staining was observed in the basal layer of all normal endocervical glands. eIF-4E expression, which was mainly observed as cytoplasmic staining, gradually increased in accordance with histopathologic grade in the order low-grade CIN < high-grade CIN < ISCC (P < .001) and, in particular, was strongly detected in all ISCC cases.
  • Furthermore, real-time quantitative reverse transcriptase polymerase chain reaction revealed that eIF-4E expression in tumor was significantly enhanced versus normal cervical tissues (P = .037).
  • These results suggest that eIF-4E may play a significant role in tumor progression of cervical neoplasia and may represent useful markers for malignant transformation of cervical squamous cells.
  • [MeSH-major] Biomarkers, Tumor / analysis. Eukaryotic Initiation Factor-4E / biosynthesis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Female. Humans. Immunohistochemistry. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16260273.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Eukaryotic Initiation Factor-4E; 0 / RNA, Messenger
  •  go-up   go-down


13. Sakurai H, Suzuki Y, Nonaka T, Ishikawa H, Shioya M, Kiyohara H, Katoh H, Nakayama Y, Hasegawa M, Nakano T: FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value. Gynecol Oncol; 2006 Mar;100(3):601-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
  • PURPOSE: We evaluated the use of positron emission tomography (PET) with fluorine-18-labeled fluoro-2-deoxy-d-glucose (FDG) in follow-up study after radiation therapy in patients with uterine cervical carcinoma.
  • Rationale for FDG-PET was the presence of symptoms in 6 patients, abnormal serum tumor marker values in 13, abnormal lesions on other diagnostic imaging modalities in 19, and patient request in 2.
  • Maximum tumor diameter and tumor volume in the corresponding disease were estimated by computed tomography (CT) or magnetic resonance imaging (MRI).
  • Three false-positive cases were a localized pneumonitis, a benign pubic bone fracture, and a fibrosis after interstitial brachytherapy.
  • Regarding tumor volume measurement, good correlation between maxSUV on FDG-PET and tumor volume was obtained (lung metastases, P = 0.03; extrapelvic nodes, P < 0.0001).
  • CONCLUSION: FDG-PET is a useful tool for the detection of extrapelvic lesions during the follow-up period after radiation therapy for cervical cancer.
  • This study suggests that FDG uptake is associated with tumor volume, and FDG-PET has limitations in the detection of lesions less than 1 cm3 or microscopic disease.
  • Careful diagnostic agreement between PET and CT/MRI for positive but benign lesions, such as inflammation and bone fracture, remains important.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Uterine Cervical Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16257440.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Sakaura H, Ohshima K, Iwasaki M, Yoshikawa H: Intra-extradural plexiform schwannoma of the cervical spine. Spine (Phila Pa 1976); 2007 Oct 1;32(21):E611-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-extradural plexiform schwannoma of the cervical spine.
  • OBJECTIVE: To describe the clinical and radiographic features of an extremely rare case with intra-extradural plexiform schwannoma of the cervical spine.
  • SUMMARY OF BACKGROUND DATA: Plexiform schwannoma is a rare neurogenic tumor that predominantly occurs in the dermis and subcutis.
  • No cases of intra-extradural plexiform schwannoma of the cervical spine have previously been reported.
  • Preoperative magnetic resonance imaging showed a multinodular inhomogeneous dumbbell-shaped tumor encroaching on the cord at C3-C4.
  • T1-weighted imaging showed the tumor as inhomogeneous with slightly higher intensity than muscle.
  • T2-weighted imaging demonstrated a multinodular inhomogeneous tumor with much higher intensity than muscle, and each nodule of the tumor displayed a peripheral rim of higher intensity and central relatively lower intensity.
  • RESULTS: Through hemi-laminectomy from C3-C4 and facetectomy of the left side of C3-C4, the intradural parts of the multinodular tumor were completely extirpated and extradural parts of the multinodular tumor were enucleated as much as possible.
  • Gross examination of the tumor showed yellowish-white soft contents that were encapsulated and multilobulated.
  • Histologic examination revealed benign schwannoma.
  • [MeSH-major] Cervical Vertebrae / pathology. Neurilemmoma / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906563.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Feng Y, Zhang GX, Wang H, Hu YS, Wang XF, Zheng LF: [Comparison between Gd-DTPA-enhanced MRI and USPIO-enhanced MRI in diagnosing benign and metastatic cervical lymph nodes in rabbit models]. Zhonghua Zhong Liu Za Zhi; 2010 Nov;32(11):813-8
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison between Gd-DTPA-enhanced MRI and USPIO-enhanced MRI in diagnosing benign and metastatic cervical lymph nodes in rabbit models].
  • METHODS: Reactive hyperplastic cervical lymph node model was established in 18 rabbits as hyperplasia group, and tumor-bearing lymph node model was established in another 18 rabbits as tumor group.
  • RESULTS: In the tumor group, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of Gd-DTPA-enhanced MRI were 62.5%, 91.3%, 88.2%, 70.0% and 76.6%, respectively.
  • [MeSH-major] Dextrans. Gadolinium DTPA. Liver Neoplasms, Experimental / pathology. Lymph Nodes / pathology. Magnetic Resonance Imaging / methods. Magnetite Nanoparticles. Pseudolymphoma / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21223685.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Magnetite Nanoparticles; 0 / ferumoxtran-10; K2I13DR72L / Gadolinium DTPA; K3R6ZDH4DU / Dextrans
  •  go-up   go-down


16. Gupta R, Singh S, Nigam S, Khurana N: Benign vascular tumors of female genital tract. Int J Gynecol Cancer; 2006 May-Jun;16(3):1195-200

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign vascular tumors of female genital tract.
  • The vascular tumors occurred most commonly in ovary (six), followed by vulva (two), and one each in cervix and vagina.
  • Clinical diagnoses ranged from cystadenoma in ovarian tumors to endocervical polyp in cervical tumor.
  • Histologically, all were benign vascular neoplasms, ranging from hemangioma (five), lymphangioma (one), lymphangioma circumscriptum (one) to angiomatosis (two) and arteriovenous malformation (one).
  • Vascular lesions of cervix and vulvovaginal region pose special problem during pregnancy.
  • [MeSH-major] Genital Neoplasms, Female / diagnosis. Genitalia, Female / blood supply. Vascular Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Angiomatosis / diagnosis. Arteriovenous Malformations / diagnosis. Female. Genital Diseases, Female / diagnosis. Hemangioma / diagnosis. Humans. Lymphangioma / diagnosis. Middle Aged. Ovarian Neoplasms / diagnosis. Retrospective Studies. Uterine Cervical Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803506.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Junming M, Cheng Y, Dong C, Jianru X, Xinghai Y, Quan H, Wei Z, Mesong Y, Dapeng F, Wen Y, Bin N, Lianshun J, Huimin L: Giant cell tumor of the cervical spine: a series of 22 cases and outcomes. Spine (Phila Pa 1976); 2008 Feb 1;33(3):280-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the cervical spine: a series of 22 cases and outcomes.
  • STUDY DESIGN: A consecutive series of 22 giant cell tumor (GCTs) of the cervical spine which underwent surgical treatment was observed from 1990-2003.
  • OBJECTIVE: This study reviews the clinical patterns and follow-up data of (GCT) of bone arising in the cervical spine which underwent surgical treatment.
  • SUMMARY OF BACKGROUND DATA: GCTs of bone are common, aggressive, or low-grade malignant tumors that occur infrequently in the spine above the sacrum, and their presence in the cervical vertebrae is even more exceptional.
  • Though surgical resection of GCT arising in the cervical spine is commonly regarded as a recommended treatment method, it is still a challenge to achieve satisfactory results, especially for the late or recurrent cases, and there are few large series of cases reported with long-term follow-up of this tumor that are found in special segments in the literature.
  • METHODS: All clinical and follow-up data of 22 cases of GCT arising in cervical spine which received surgical treatment in our spine center from January 1990-December 2003 were collected.
  • One special lesion located in the posterior element of C7 received "en bloc" resection.
  • For reconstructing the stability of the cervical spine, we used autologous ilium for pure bone graft, or titanium plate and titanium mesh for anterior instrumented fusion or anterior and posterior combined instrumented fusion.
  • RESULTS: One patient with C1-C2 GCT (vertebral body and posterior element involvement) who received subtotal resection of the tumor showed aggravation of neurologic deficit and died shortly after the surgery.
  • CONCLUSION: GCT of the cervical spine easily onsets between 20 and 40 years of age.
  • As a kind of benign but local aggressive or low potential malignancy tumor, we should take an aggressive attitude to excise the tumor as much as possible while reserving the neural function as a precondition.
  • Unlike in the thoracic and lumbar spine, a strictly "en bloc" resection is often not a feasible option because of the involvement of critical neurovascular structures.
  • [MeSH-major] Bone Neoplasms / surgery. Cervical Vertebrae / surgery. Giant Cell Tumor of Bone / surgery. Spinal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Diskectomy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Postoperative Complications. Spinal Fusion. Survival Rate. Treatment Outcome


18. Aximu D, Azad A, Ni R, Colgan T, Nanji S: A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int J Gynecol Pathol; 2009 Mar;28(2):114-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
  • The histopathologic distinction of cervical adenocarcinoma in situ (AIS) and invasive adenocarcinoma (AC) from some benign endocervical lesions can be challenging.
  • ProEx C immunohistochemical staining was performed on sections from formalin-fixed, paraffin-embedded tissue of 65 cervical tissues including 48 non-neoplastic cervices (normal [n=10], microglandular hyperplasia [n=10], tubal metaplasia [n=11], cervical endometriosis [n=7], reactive endocervix [n=10]) and 17 cervices with glandular malignancy (AIS [n=12] and AC [n=5]).
  • The median and distribution of scores for both prevalence and intensity was compared for AIS versus each of the 5 benign cervical lesions using a Mann-Whitney U test.
  • The median and distribution of prevalence of immunohistochemical staining for AIS was different from all benign mimics, but the intensity of staining for AIS did overlap with some mimics as it was not significantly different from endometriosis, microglandular hyperplasia, and reactive endocervix.
  • ProEx C reagent has potential as an adjunctive testing tool in the histopathologic diagnosis of both AIS and AC, particularly in difficult cases with small biopsies or foci of disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. Cervical Intraepithelial Neoplasia / diagnosis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Minichromosome Maintenance Complex Component 2. Pilot Projects. Reagent Kits, Diagnostic

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188825.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


19. Park KJ, Soslow RA: Current concepts in cervical pathology. Arch Pathol Lab Med; 2009 May;133(5):729-38
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in cervical pathology.
  • CONTEXT: The correct diagnosis and reporting of cervical in situ and invasive carcinoma are essential for the appropriate clinical management of patients with human papillomavirus-associated disease.
  • OBJECTIVES: To review common mistakes made in the diagnosis of cervical dysplasia and invasive carcinoma, describe variants and benign mimics of high-grade squamous intraepithelial lesion and adenocarcinoma in situ, and discuss available ancillary studies that can be useful in making the distinctions as well as to review important factors related to prognosis that should be included in the pathology report.
  • CONCLUSIONS: There are many mimics and variants of cervical squamous and glandular lesions that can be resolved with ancillary studies and careful histologic examination.
  • Prognostically important features, such as tumor size, presence of vascular invasion, and margin status, should always be included in the pathology report.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Papillomavirus Infections / diagnosis. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415947.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 74
  •  go-up   go-down


20. Cimpean AM, Saptefrati L, Ceausu R, Raica M: Characterization of endoglin and Ki-67 expression in endothelial cells from benign and malignant lesions of the uterine cervix. Pathol Int; 2009 Oct;59(10):695-700
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of endoglin and Ki-67 expression in endothelial cells from benign and malignant lesions of the uterine cervix.
  • CD105 is a more specific marker of activated endothelial cells from tumor vessels and Ki-67 is used to assess the proliferation status of both tumor and endothelial cells.
  • The aim of the present study was to evaluate the status of endothelial cells using CD105 and Ki-67 immunohistochemistry in benign and malignant lesions of the uterine cervix.
  • Double stain for CD105/Ki-67 in benign and malignant lesions of the uterine cervix showed that these two markers had divergent expression on endothelial cells from associated tumor blood vessels dependent on lesion type and proliferation status of tumor cells.
  • Absence of CD105/Ki-67 coexpression in endothelial cells was correlated with histopathology of the uterine cervix lesions and tumor proliferative status.
  • The present findings suggest that CD105 expression is an early event, specific for premalignant lesions of the uterine cervix, while endothelial proliferation assessed on Ki-67 combined with the lack of CD105 expression is often associated with invasive cervical carcinoma.
  • [MeSH-major] Antigens, CD / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Cervix Uteri / metabolism. Endothelial Cells / metabolism. Ki-67 Antigen / metabolism. Precancerous Conditions / metabolism. Receptors, Cell Surface / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Metaplasia. Neovascularization, Pathologic

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788614.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Ki-67 Antigen; 0 / Receptors, Cell Surface
  •  go-up   go-down


21. López-Morales D, Velázquez-Márquez N, Valenzuela O, Santos-López G, Reyes-Leyva J, Vallejo-Ruiz V: Enhanced sialyltransferases transcription in cervical intraepithelial neoplasia. Invest Clin; 2009 Mar;50(1):45-53
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced sialyltransferases transcription in cervical intraepithelial neoplasia.
  • Altered sialylation observed during oncogenic transformation, tumor metastases and invasion, has been associated with enhanced sialyltransferases (STs) transcription.
  • Increased mRNA expression of STs (ST6Gal I, ST3Gal III) has been detected in invasive cervical squamous cell carcinoma.
  • A study of the sialic acid concentration in local tissue of cervix and in serum showed a slight elevation in benign inflammatory lesions and a moderate elevation in severe neoplasia, but to date, altered expression of STs in cervical intraepithelial neoplasia has not yet been evaluated.
  • This study investigates the changes in mRNA expression of three STs (ST6Gal I, ST3Gal III, and ST3Gal IV) in cervical intraepithelial lesions (CIN).
  • Alterations of these STs mRNA expression were examined in 35 cervix specimens classified as normal, CIN 1, CIN 2 and CIN 3, by semiquantitative reverse transcription-polymerase chain reaction, mRNA expression of the three STs was enhanced in CIN 1, CIN 2 and CIN 3 with respect to normal tissue, with a significant difference of p < 0.001 (Mann-Whitney U test) for all the enzymes.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / enzymology. Neoplasm Proteins / genetics. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Sialyltransferases / genetics. Uterine Cervical Neoplasms / enzymology

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19418726.001).
  • [ISSN] 0535-5133
  • [Journal-full-title] Investigación clínica
  • [ISO-abbreviation] Invest Clin
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Venezuela
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.4.99.- / Sialyltransferases; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


22. Kohrenhagen N, Volker HU, Kapp M, Dietl J, Kammerer U: Increased expression of galectin-1 during the progression of cervical neoplasia. Int J Gynecol Cancer; 2006 Nov-Dec;16(6):2018-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of galectin-1 during the progression of cervical neoplasia.
  • Galectin-1 was found to be overexpressed in various cancer cells and the corresponding benign tissue.
  • Therefore, it has been described as a marker for tumor progression in some malignancies.
  • In the current study, the expression of galectin-1 was examined in 80 formalin-fixed, paraffin-embedded cervical tissues: 20 benign cervical specimen, 20 low-grade squamous intraepithelial lesions (LGSIL), 20 high-grade squamous intraepithelial lesions (HGSIL), and 20 invasive squamous cell carcinomas (ISCC).
  • Immunohistochemical analyses showed that the intensity of the galectin-1 expression on stromal cells next to the transformed cells increased according to the pathologic grade: benign cervical tissue < LGSIL < HGSIL < ISCC (P < 0.001).
  • These results suggest that galectin-1 expression on stromal cells increases with the histopathologic grade of cervical tissues, and it can be concluded that this increase is associated with the progression of cervical neoplasia.
  • [MeSH-major] Galectin 1 / metabolism. Gene Expression Regulation, Neoplastic. Up-Regulation. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177840.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Galectin 1
  •  go-up   go-down


23. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
  • Mammaglobin (MGB), a secretory protein belonging to the uteroglobin/Clara cell protein family, is a sensitive marker for breast carcinoma, but is also reported to be expressed in the female genital tract and its neoplasms.
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • Reduction of MGB staining was seen in transition from benign epithelium to AIS.
  • Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2 tumor types.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism
  • [MeSH-minor] Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


24. Bhatnagar AK, Gerszten PC, Ozhasaglu C, Vogel WJ, Kalnicki S, Welch WC, Burton SA: CyberKnife Frameless Radiosurgery for the treatment of extracranial benign tumors. Technol Cancer Res Treat; 2005 Oct;4(5):571-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CyberKnife Frameless Radiosurgery for the treatment of extracranial benign tumors.
  • Limited data exists for the use of radiosurgery for benign extracranial tumors.
  • The purpose of this study was to evaluate the feasibility, toxicity, and local control of patients with benign extracranial lesions treated with the CyberKnife Frameless Radiosurgery System.
  • From September 2001 thru January 2004, 59 benign tumors in 44 patients were treated using the CyberKnife a frameless image-guided radiosurgery system.
  • The anatomic locations of these tumors were spinal (25 cervical, four thoracic, 14 lumbar, and two sacral), neck (eight), orbital (three), brainstem (one), and foramen magnum (one).
  • The median tumor dose delivered was 16.0 Gy to the 80% isodose line (range 10-31 Gy).
  • The median tumor volume was 4.3 cc (range 0.14-98.6 cc).
  • This study suggests that CyberKnife Radiosurgery is a safe and efficacious treatment modality for benign tumors, even for those patients with recurrent previously irradiated lesions.
  • [MeSH-major] Brain Neoplasms / surgery. Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Neurofibroma / surgery. Safety. Spinal Cord Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173828.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Zalutskiĭ IV, Vishnevskaia EE, Kurian LM: [Methodologic and organizational principles of selective screening for cervical, endometrial and ovarian carcinoma]. Vopr Onkol; 2006;52(1):74-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Methodologic and organizational principles of selective screening for cervical, endometrial and ovarian carcinoma].
  • Data are presented on screening for cervical (CC), endometrial (UC) and ovarian (OC) carcinoma carried out in the Republic of Belarus as well as a discussion of logistic and methodologic aspects of the problem.
  • Local "centers for prevention and early diagnosis of reproductive organ tumors" form the backbone of the national system.
  • A comparison of data on selective screening for CC, UC and OC with those of mass prophylactic examinations and cytological screening for CC showed that selective detection rates for cervical dysplasia were 14 times, and in situ cervical carcinoma--4 times higher.
  • Consequently, the share of endometrial hyperplasia cases rose 3.5-fold, uterine myoma--3-fold and adenomyosoma--1.5-fold. identified atypical endometrial hyperplasia, in situ cancer and endometrial stage I in "clinically healthy" women.
  • The rates of detection of such tumor-like ovarian formations as follicular, lutein, endometrioid and para-ovarian cysts increased 2.3-fold, benign tumors--2.2-fold and polycystosis--twofold.
  • [MeSH-major] Cancer Care Facilities / organization & administration. Endometrial Neoplasms / epidemiology. Mass Screening / methods. Mass Screening / organization & administration. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Cysts / diagnosis. Endometrial Hyperplasia / epidemiology. Female. Humans. Incidence. Middle Aged. Republic of Belarus. Uterine Cervical Dysplasia / epidemiology


26. El-Khashab M, Koral K, Bowers DC, Johnson-Welch S, Swift D, Nejat F: Intermediate grade meningeal melanocytoma of cervical spine. Childs Nerv Syst; 2009 Apr;25(4):407-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intermediate grade meningeal melanocytoma of cervical spine.
  • BACKGROUND: Meningeal melanocytoma is a rare, benign melanotic tumor of the leptomeninges, which occurs anywhere in the cranial or spinal regions but most commonly in supratentorial and thoracic spine regions.
  • The literature on this entity consists of case reports; therefore, there is no agreement on the most effective therapy of this tumor, although total excision seems to be the best therapeutic option.
  • The tumor was removed subtotally through cervical laminotomy followed by rapid improvement of most neurological deficits.
  • This tumor was unusual because of its very hyperintense homogenous signal on T1-weighted images, invasion of the arachnoid membrane, and extension into the neural foramina.
  • Black dots on the surface of the cord were thought to represent an organized blood clot until the frozen section suggested a melanocytic tumor.
  • CONCLUSION: Melanocytic tumors should be considered in the differential diagnosis when a hyperintense lesion of the leptomeninges is identified on T1-weighted images or a very dark mass similar to charcoal or organized hematoma is found in the surgical field.
  • The best management is complete tumor resection, but radiotherapy is reserved in cases of subtotal resection and multiple lesions.
  • Locally aggressive nature of tumor and possibility of recurrence warrant regular follow-up.
  • [MeSH-major] Cervical Vertebrae. Medulloblastoma / pathology. Meningeal Neoplasms / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Meninges / pathology. Meninges / surgery. Spinal Cord / pathology. Spinal Cord / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 2003 Mar;59(3):200-10 [12681556.001]
  • [Cites] J Neurosurg. 2004 Mar;100(3 Suppl Spine):287-90 [15029918.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):745-54 [10403296.001]
  • [Cites] Neurosurgery. 1992 Nov;31(5):958-61 [1436425.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Mar-Apr;12 (2):315-6 [1902034.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Jan;17(1):55-60 [8770250.001]
  • [Cites] J Neurosurg Spine. 2007 May;6(5):451-4 [17542513.001]
  • [Cites] Neurosurgery. 1992 Nov;31(5):945-8 [1436422.001]
  • [Cites] Childs Nerv Syst. 2006 Jun;22(6):556-61 [16491422.001]
  • [Cites] J Neurosurg. 1998 May;88(5):890-4 [9576259.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jan;18(1):180-2 [9010539.001]
  • [Cites] J Neurosurg. 2001 Oct;95(2 Suppl):225-31 [11599841.001]
  • (PMID = 19139906.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Hunter CL, Pacione D, Hornyak M, Murali R: Giant-cell tumors of the cervical spine: case report. Neurosurgery; 2006 Nov;59(5):E1142-3; discussion E1143
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant-cell tumors of the cervical spine: case report.
  • OBJECTIVE: Giant-cell tumors of bone are rare, benign neoplasms that occur infrequently in the spine above the sacrum, and their presence in the cervical vertebrae is even more exceptional.
  • Although complete en bloc surgical resection is difficult in the cervical spine, treatment with adjuvant radiotherapy has been considered controversial because of a small risk of malignant transformation.
  • The authors report two cases of giant-cell tumors in the cervical vertebrae that were treated successfully with surgical excision and postoperative radiation as well as long-term follow-up.
  • INTERVENTION: In one case, the tumor was treated by anterior resection, then by laminectomy and instrumented fusion, and finally by adjuvant postoperative radiotherapy.
  • However, the tumor recurred, and, after several surgical procedures, external beam radiotherapy was administered.
  • The patients have been followed for 17 and 11 years, respectively, with no evidence of tumor recurrence.
  • However, complete resection is often not a feasible option for tumors in the cervical spine because of involvement of critical neurovascular structures.
  • [MeSH-major] Cervical Vertebrae / surgery. Giant Cell Tumor of Bone / diagnosis. Giant Cell Tumor of Bone / surgery. Laminectomy / methods. Spinal Neoplasms / diagnosis. Spinal Neoplasms / surgery. Thoracic Vertebrae / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143206.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Rabban JT, McAlhany S, Lerwill MF, Grenert JP, Zaloudek CJ: PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Am J Surg Pathol; 2010 Feb;34(2):137-46
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
  • Mesonephric remnants of the cervix are vestiges of the embryonic mesonephric system which typically regresses during female development.
  • The differential diagnosis of exuberant mesonephric hyperplasia includes minimal deviation adenocarcinoma of the cervix, a tumor with deceptively bland morphology for which no reliable diagnostic biomarkers currently exist.
  • PAX2 encodes a transcription factor necessary in the development of the Wolffian duct system, and the protein is expressed in several tumors of mesonephric origin, including renal cell carcinoma, Wilm tumor, and nephrogenic adenoma.
  • We hypothesized that PAX2 may also be expressed in mesonephric lesions of the cervix and may distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma of the cervix.
  • PAX2 was expressed in normal endocervical glands (including tunnel clusters and Nabothian cysts) (86 of 86), lobular endocervical glandular hyperplasia (5 of 5), tubal/tuboendometrioid metaplasia (8 of 8), and cervical endometriosis (13 of 14).
  • These results suggest that PAX2 immunoreactivity may be useful to (1) distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma, (2) to distinguish lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma, and (3) to distinguish endocervical tubal metaplasia or cervical endometriosis from endocervical adenocarcinoma in situ.
  • Overall, a strong, diffuse nuclear PAX2 expression pattern in a cervical glandular proliferation predicts a benign diagnosis (positive predictive value 90%, negative predictive value 98%; P<0.001); however, PAX2 should not be interpreted in isolation from the architectural and cytologic features of the lesion as it may be expressed in some stage II endometrial adenocarcinomas involving the cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Cervix Uteri / pathology. Mesonephros / pathology. Mullerian Ducts / pathology. PAX2 Transcription Factor / metabolism. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor. Cell Nucleus / metabolism. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Immunohistochemistry / methods. Neoplasm Staging. Precancerous Conditions / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061933.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human
  •  go-up   go-down


29. Duggan MA, Akbari M, Magliocco AM: Atypical immature cervical metaplasia: immunoprofiling and longitudinal outcome. Hum Pathol; 2006 Nov;37(11):1473-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical immature cervical metaplasia: immunoprofiling and longitudinal outcome.
  • Atypical proliferations of immature cervical squamous metaplasia were reviewed and correlated with p16 and Ki-67 expression to determine whether immunoprofiling could enable more conventional classification.
  • The 172 atypias were reviewed as 3 (1.7%) negative, 54 (31.4%) benign, 60 (34.9%) AIM, 43 (25%) low-grade SIL (LSIL), and 12 (6.9%) high-grade SIL (HSIL).
  • Benign diagnoses correlated significantly with a low index (1%-15%) and p16 negative or focal profile (P = .01).
  • p16 and Ki-67 immunoprofiling are reliable in reclassifying some atypical proliferations of immature squamous metaplasia as HSIL and some as benign.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervical Intraepithelial Neoplasia / pathology. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Ki-67 Antigen / analysis. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949917.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen
  •  go-up   go-down


30. Lian X, Zhao J, Hou T, Ma H, Chen Z: Benign intraspinal osteoblastoma stemming from C7 lamina in cervicothoracic junction: a case report. Spine (Phila Pa 1976); 2006 Nov 1;31(23):E895-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign intraspinal osteoblastoma stemming from C7 lamina in cervicothoracic junction: a case report.
  • STUDY DESIGN: A case report of a rare benign osteoblastoma successfully treated with total en bloc excision.
  • SUMMARY OF BACKGROUND DATA: A rare case of massive benign osteoblastoma stemming from left side lamina of C7 and extension to spinal canal from C6 to T1 resulting in spinal cord compressed severely is reported.
  • A massive neoplasm located in intraspinal cervicothoracic junction and the spinal cord compressed severely was shown in radiographs, MRI, and CT.
  • The neoplasm was removed totally with instrumentation performed in surgical intervention.
  • Recurrence of the tumor was not seen at the final follow-up.
  • [MeSH-major] Cervical Vertebrae. Osteoblastoma / diagnosis. Osteoblastoma / surgery. Spinal Canal / surgery. Spinal Neoplasms / diagnosis. Spinal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Female. Humans. Magnetic Resonance Imaging. Pain / etiology. Spinal Cord Compression / diagnosis. Spinal Cord Compression / etiology. Thoracic Vertebrae / radiography. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17077728.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Schlott T, Eiffert H, Bohne W, Landgrebe J, Brunner E, Spielbauer B, Knight B: Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue. Gynecol Oncol; 2005 Sep;98(3):409-19
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue.
  • OBJECTIVES: The obligate intracellular bacterium Chlamydia trachomatis is frequently found in association with benign proliferative, pre-neoplastic and malignant changes in cervical epithelium.
  • The present study addresses the possible role of C. trachomatis infection of the uterine cervix in modulating human cancer gene expression.
  • Forty specimens of cervix dissected from the transformation zone had previously tested negative for HPV and positive for C. trachomatis by standard DNA PCR (20).
  • The cultures showed a 2-fold decrease in the expression of the gene coding for the tumor suppressor caveolin-1, and increased expression of the oncogene C-myc, a promoter of cervical carcinogenesis.
  • In tissues from the Chlamydia-infected cervical transformation zone, real-time RT-PCR demonstrated a highly significant average 4.7-fold reduction of caveolin-1 mRNA (P < or = 0.0001) and an average 2.1-fold increase in C-myc (P < 0.05).
  • CONCLUSIONS: Human ITFgamma-treated fibroblasts as well as non-neoplastic cervical tissues responded to C. trachomatis with a strong down-regulation of caveolin-1 mRNA and a light up-regulation of C-myc mRNA.
  • This study reveals possible mechanisms by which C. trachomatis infection may contribute to neoplastic changes in the transformation of uterine cervix.
  • [MeSH-major] Caveolins / genetics. Cell Transformation, Neoplastic / genetics. Cervix Uteri / microbiology. Chlamydia trachomatis / physiology. Genes, Tumor Suppressor / physiology. Genes, myc / genetics. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / microbiology


32. Logié A, Dunois-Lardé C, Rosty C, Levrel O, Blanche M, Ribeiro A, Gasc JM, Jorcano J, Werner S, Sastre-Garau X, Thiery JP, Radvanyi F: Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet; 2005 May 1;14(9):1153-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.
  • The identification in multiple myeloma and in two epithelial cancers-bladder and cervical carcinomas-of somatic FGFR3 mutations identical to the germinal activating mutations found in skeletal dysplasias, together with functional studies, have suggested an oncogenic role for this receptor.
  • Although acanthosis nigricans, a benign skin tumor, has been found in some syndromes associated with germinal activating mutations of FGFR3, the role of activated FGFR3 in the epidermis has never been investigated.
  • Mice expressing the transgene developed benign epidermal tumors with no sign of malignancy.
  • These skin lesions had features in common with acanthosis nigricans and other benign human skin tumors, including seborrheic keratosis, one of the most common benign epidermal tumors in humans.
  • A large proportion of these tumors (39%) harbored somatic activating FGFR3 mutations, identical to those associated with skeletal dysplasia syndromes and bladder and cervical neoplasms.
  • Our findings directly implicate FGFR3 activation as a major cause of benign epidermal tumors in humans.
  • [MeSH-major] Gene Expression. Keratosis, Seborrheic / genetics. Point Mutation. Protein-Tyrosine Kinases / genetics. Receptors, Fibroblast Growth Factor / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15772091.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Fibroblast Growth Factor; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Fgfr3 protein, mouse; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


33. Oudidi A, Hachimi H, El Alami MN: [Desmoid tumor of the parotid gland]. Rev Stomatol Chir Maxillofac; 2006 Dec;107(6):470-3
Genetic Alliance. consumer health - Desmoid Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoid tumor of the parotid gland].
  • [Transliterated title] Tumeur desmoïde de la glande parotide.
  • INTRODUCTION: Desmoid tumor is a benign microscopic tumor that belongs to the group of the deep fibromatosis.
  • Physical examination revealed a tumor in the parotid gland, which was hard and adherent deeply, measuring 4 cm/3 cm and sensitive to palpation; without satellite nodes nor facial paralysis.
  • Pathology was in favor of a desmoid tumor.
  • Although very rare, the cervical localizations are especially aggressive.
  • [MeSH-major] Fibromatosis, Aggressive / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195002.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


34. Selch MT, Lin K, Agazaryan N, Tenn S, Gorgulho A, DeMarco JJ, DeSalles AA: Initial clinical experience with image-guided linear accelerator-based spinal radiosurgery for treatment of benign nerve sheath tumors. Surg Neurol; 2009 Dec;72(6):668-74; discussion 674-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial clinical experience with image-guided linear accelerator-based spinal radiosurgery for treatment of benign nerve sheath tumors.
  • Tumor location was cervical 11, lumbar 10, and thoracic 4.
  • Tumor size varied from 0.9 to 4.1 cm (median, 2.1 cm).
  • Tumor size remained stable in 18 cases, and 7 (28%) demonstrated more than 2 mm reduction in tumor size.
  • CONCLUSIONS: Results of this limited experience indicate linear accelerator-based spinal radiosurgery is feasible for treatment of benign nerve sheath tumors.
  • [MeSH-major] Neurilemmoma / surgery. Peripheral Nervous System Neoplasms / surgery. Radiosurgery / instrumentation. Spinal Nerves / surgery. Surgery, Computer-Assisted / instrumentation
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Neurofibromatosis 1 / diagnosis. Neurofibromatosis 1 / surgery. Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / surgery. Neurologic Examination. Postoperative Complications / diagnosis. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19608232.001).
  • [ISSN] 1879-3339
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Nishio S, Tsuda H, Fujiyoshi N, Ota S, Ushijima K, Sasajima Y, Kasamatsu T, Kamura T, Matsubara O: Clinicopathological significance of cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia. Pathol Res Pract; 2009;205(5):331-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia.
  • Lobular endocervical glandular hyperplasia (LEGH) is usually assumed to be a benign tumor-like lesion of the glands of the uterine cervix.
  • However, LEGH has been associated with obvious cervical adenocarcinoma.
  • We microscopically examined the presence or absence of LEGH components in 95 stage Ib cervical adenocarcinomas.
  • The mortality rate of tumor recurrence was 25% (4 of 16) in patients whose tumors had LEGH components, and 21.5% (17 of 79) in those whose tumors had no LEGH components.
  • Early cervical adenocarcinoma was relatively frequently associated with LEGH components.
  • LEGH may be one of the factors related to the development of cervical adenocarcinoma, but adenocarcinoma with LEGH components does not necessarily develop into a highly aggressive "adenoma malignum. "
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19167836.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


36. Pennekamp W, Peters S, Schinkel C, Kuhnen C, Nicolas V, Muhr G, Frangen TM: Aneurysmal bone cyst of the cervical spine (2008:7b). Eur Radiol; 2008 Oct;18(10):2356-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneurysmal bone cyst of the cervical spine (2008:7b).
  • Aneurysmal bone cysts (ABC) are rare, benign, but locally destructive bone tumors.
  • They occur in the spine in 14% of cases, but only 2% are found in the cervical spine.
  • This case report presents a 16-year-old female with an expansive aneurysmatic bone cyst with extensive bone destruction and instability in the cervical segments C1 and C2.
  • In CT and MRI, there was a soft-tissue tumor mass with multiple cysts and fluid-fluid levels within these cysts, as well as contrast enhancement of the cyst wall and the tissue among the cysts.
  • The tumor was resected en bloc, after which the patient underwent adjuvant radiation therapy.
  • [MeSH-major] Bone Cysts, Aneurysmal / diagnosis. Cervical Vertebrae / diagnostic imaging. Cervical Vertebrae / pathology. Magnetic Resonance Imaging. Spinal Diseases / diagnosis. Tomography, X-Ray Computed


37. Liang J, Mittal KR, Wei JJ, Yee H, Chiriboga L, Shukla P: Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions. Int J Gynecol Pathol; 2007 Jan;26(1):71-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions.
  • Early detection of premalignant and malignant glandular lesions of the uterine cervix and their distinction from benign mimics is crucial but sometimes difficult.
  • In this study, we investigated utility of expression of p16, CEA, Ki67, p53 and ER/PR in evaluating the benign, premalignant, and malignant glandular lesions of the uterine cervix.
  • A total of 35 cervical cone or LEEP cases were collected including 14 adenocarcinoma in situ (AIS), 7 endocervical glandular dysplasia (EGD), and 14 benign mimics (BM).
  • There was a loss of ER/PR in cervical AIS, but not in EGD.
  • Our results indicate that the Silverberg scoring system is a useful tool in differential diagnosis of cervical glandular lesions for increased diagnostic accuracy and interobserver agreement.
  • Most cervical glandular lesions can be differentiated by using a combination of histological scores with a panel of immunomarkers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Carcinoembryonic Antigen / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Diagnosis, Differential. Female. Humans. Ki-67 Antigen / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Suppressor Protein p53 / metabolism


38. Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, Hirashiki K, Seki K, Shozu M: Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol; 2009 Jan;20(1):71-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum YKL-40 as a marker for cervical adenocarcinoma.
  • BACKGROUND: The current study examined the clinical usefulness of YKL-40 in detection and prognosis of uterine cervical cancer.
  • PATIENTS AND METHODS: Serum levels of YKL-40, cancer antigen 125 (CA 125), carbohydrate antigen 19-9 (CA19-9), and squamous cell carcinoma (SCC) antigen were determined by enzyme-linked immunosorbent assay in women with benign gynecologic disease (n=24), cervical malignancy (SCC, n=104; adenocarcinoma, n=37), and age-matched healthy controls (n=45).
  • Tumor-associated macrophages showed immunoreactivity for YKL-40 in 2 of 28 adenocarcinoma tissue samples, but adenocarcinoma cells themselves were nonimmunoreactive in all samples.
  • Multivariate Cox regression analysis revealed that elevated pretreatment YKL-40 levels predicted unfavorable prognosis, independent of International Federation of Gynecology and Obstetrics stage and age at diagnosis.
  • CONCLUSIONS: Pretreatment serum YKL-40 level is a possible prognosticator of cervical adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18723551.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adipokines; 0 / Biomarkers, Tumor; 0 / CHI3L1 protein, human; 0 / Glycoproteins; 0 / Lectins
  •  go-up   go-down


39. Vaid L, Gupta M, Gupta N, Singh PP: Bleomycin sclerotherapy in a rare case of adult-onset cervical lymphangioma. Ear Nose Throat J; 2010 Jan;89(1):E23-6
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bleomycin sclerotherapy in a rare case of adult-onset cervical lymphangioma.
  • Cervical lymphangioma in adults is a rare, benign tumor.
  • We describe the case of a 60-year-old woman who presented with two lymphangiomas in the cervical area-one in the upper cervical area just below the angle of the mandible and the other in the submental area.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Bone Neoplasms / drug therapy. Lymphangioma / drug therapy. Sclerotherapy / methods

  • Genetic Alliance. consumer health - Lymphangioma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20155685.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


40. Yang YC, Lee ZY, Wu CC, Chen TC, Chang CL, Chen CP: CXCR4 expression is associated with pelvic lymph node metastasis in cervical adenocarcinoma. Int J Gynecol Cancer; 2007 May-Jun;17(3):676-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4 expression is associated with pelvic lymph node metastasis in cervical adenocarcinoma.
  • The aim of this study is to investigate the expression of CXCR4 receptor in cervical adenocarcinoma and related mechanisms involved in pelvic lymph node metastasis.
  • Immunohistochemistry was used to evaluate the expression of CXCR4 and the association of pelvic lymph node metastasis in archived tissue from clinical stage IB cervical adenocarcinomas (n = 37) and from benign specimens obtained at hysterectomy for other causes (n = 48).
  • The HeLa cell (cervical adenocarcinoma-derived cell) line that expresses CXCR4 was used to study the interaction between the CXCR4 receptor and stromal cell-derived factor 1alpha (SDF-1alpha).
  • Only 25% of the benign specimens had weak or negative staining for CXCR4.
  • We conclude CXCR4 expression is associated with cervical adenocarcinoma cell migration and proliferation, and primary cervical adenocarcinoma cells expressing CXCR4 are significantly more likely to metastasize to pelvic lymph nodes.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Metastasis. Receptors, CXCR4 / metabolism. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Cell Survival / drug effects. Chemokine CXCL12. Chemokines, CXC / metabolism. Chemokines, CXC / pharmacology. Female. HeLa Cells. Humans. Lymph Nodes / metabolism. Middle Aged. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Oncogene Protein v-akt / metabolism. Pelvis. U937 Cells

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504381.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Receptors, CXCR4; EC 2.7.11.1 / Oncogene Protein v-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


41. Proshutinskiĭ SD: [Surgical treatment of benign dumbbell-shaped intra-extravertebral tumors]. Zh Vopr Neirokhir Im N N Burdenko; 2009 Oct-Dec;(4):42-6; discussion 46
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of benign dumbbell-shaped intra-extravertebral tumors].
  • In 24 cases (50%) tumors were located in cervical region, in 15 (31.2%) in thoracic region and in 9 (18.7%) in lumbosacral region.
  • RESULTS AND CONCLUSIONS: The results of our study showed that total one-stage tumor removal is optimal.
  • Selection of approach is based on tumor location.
  • In cervical level depending on placement of tumors we used posterior approach, posterior lateral approach, and "far lateral" approach.
  • [MeSH-major] Cervical Vertebrae / surgery. Neurofibroma / surgery. Neuroma / surgery. Spinal Neoplasms / surgery. Thoracic Vertebrae / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20143611.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


42. Moore T, McLain RF: Image-guided surgery in resection of benign cervicothoracic spinal tumors: a report of two cases. Spine J; 2005 Jan-Feb;5(1):109-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-guided surgery in resection of benign cervicothoracic spinal tumors: a report of two cases.
  • BACKGROUND CONTEXT: Osseous spinal tumors are an uncommon cause of persistent axial pain and muscle spasm, but even benign lesions may grow to cause deformity or neurological signs.
  • Traditional treatment approaches to resection can be debilitating even when the tumor is benign.
  • PURPOSE: Emerging technologies allow surgeons to diagnose and treat osseous neoplasms while minimizing the collateral damage caused by surgical exposure and tumor excision.
  • STUDY DESIGN: Technical considerations are presented through two cases of benign osseous neoplasm occurring in the cervicothoracic spine of competitive athletes, demonstrating the meth-ods used to provide effective treatment while maintaining maximal functional capacity.
  • METHODS: Stereotactic imaging and intraoperative guidance was used as an adjunct to tumor care in these patients.
  • Used in combination with minimally invasive, microsurgical techniques,stereotactic guidance localized and verified excision margins of benign vertebral lesions, minimizing soft tissue trauma and collateral damage.
  • CONCLUSIONS: Image guidance can accurately localize and guide excision of benign vertebral lesions while minimizing soft tissue trauma and collateral damage, allowing patients a rapid and complete return to high-demand function.
  • [MeSH-major] Osteoblastoma / surgery. Osteoma, Osteoid / surgery. Spinal Neoplasms / surgery. Surgery, Computer-Assisted / methods
  • [MeSH-minor] Adolescent. Adult. Cervical Vertebrae. Humans. Male. Minimally Invasive Surgical Procedures / methods. Pain Measurement. Prognosis. Recovery of Function. Risk Assessment. Stereotaxic Techniques. Thoracic Vertebrae. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739278.001).
  • [ISSN] 1529-9430
  • [Journal-full-title] The spine journal : official journal of the North American Spine Society
  • [ISO-abbreviation] Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Parekh DJ, Lin WC, Herrell SD: Optical spectroscopy characteristics can differentiate benign and malignant renal tissues: a potentially useful modality. J Urol; 2005 Nov;174(5):1754-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical spectroscopy characteristics can differentiate benign and malignant renal tissues: a potentially useful modality.
  • PURPOSE: Promising results of optical signals have been reported in the literature for the diagnosis of Barrett's esophagus, oral cavity lesions, brain tumor margins, cervical intraepithelial neoplasia, skin cancer and bladder cancer.
  • The potential usefulness of these techniques in renal tissues and neoplasms has not been described to date.
  • This initial study examined the feasibility of using fluorescence and diffuse reflectance spectroscopy to differentiate between malignant and benign renal tissues.
  • Pathologically confirmed benign and malignant renal samples were obtained from nephrectomy specimens from patients undergoing radical nephrectomy.
  • Fluorescence and diffuse reflectance spectra were measured from benign and malignant renal tissues.
  • RESULTS: All renal tissues, malignant or benign, contain 2 primary emission peaks-a strong one at approximately 285 nm excitation, approximately 340 nm emission (Peak A), and a weak one at approximately 340 nm excitation, approximately 460 nm emission (Peak B).
  • The intensity of Peak B from benign tissues tends to be greater than that from malignant renal tissues.
  • Empirical discrimination algorithms developed based on selected fluorescence and diffuse reflectance spectral characteristics yields accurate differentiation between benign and malignant renal tissues.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Precancerous Conditions / pathology. Spectrometry, Fluorescence
  • [MeSH-minor] Case-Control Studies. Diagnosis, Differential. Female. Humans. Kidney / pathology. Male. Reference Values. Sampling Studies. Sensitivity and Specificity. Tissue Culture Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2005 Nov;174(5):1723-4 [16217270.001]
  • (PMID = 16217277.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Liu P, Chen CL, Zeng BL, Ma B, Zhang H, Qiu YX, Chen LT: [Study of the injury to the urinary system caused by radiological vascular interventional therapy of obstetrical and gynecological benign diseases]. Zhonghua Fu Chan Ke Za Zhi; 2006 Jan;41(1):25-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of the injury to the urinary system caused by radiological vascular interventional therapy of obstetrical and gynecological benign diseases].
  • OBJECTIVE: To explore the injuries to the urinary system caused by uterine artery embolization (UAE) for treatment of obstetrical and gynecological benign diseases, including the classification, aetiology, therapy of the injuries and precaution methods.
  • METHODS: The injuries of the urinary system were reviewed in 960 cases of obstetrical and gynecological benign diseases treated with UAE by our interventional centre.
  • Of all 960 cases, 690 cases were myoma, 244 adenomyosis, 8 cervical pregnancy, 2 cornus pregnancy, 14 postpartum hemorrhage, 2 late postpartum hemorrhage.
  • The operation procedures of all five cases were bilateral uterine artery embolization, and none used microcatheter. (2) The ureter branch arising from the middle or lower part of the uterine artery supplied the middle or lower part of ureter and the length of this part of ureter is about 4 cm, the bladder branch arising from the middle or lower part of uterine artery supplied the bladder and communicated with the bladder vascular net.
  • Correlative injuries could be caused by the retroflow of embolisms into the above arteries. (3) Placement of the catheter into the upper branch of the uterine artery or the tumor vascular net, using microcatheter if necessary and notation of the retroflow in the embolization process could avoid the embolization of bladder and ureter arteries. (4) Totally 506 cases used microcatheter, the ratio was 52.7%.
  • CONCLUSIONS: Injuries to the urinary system could occur in UAE for treatment of obstetrical and gynecological benign diseases, which can be prevented by carefully differentiating the vascular communicating branch and the conditions of branches, and embolization of the upper branch of uterine artery can avoid the injury.
  • [MeSH-major] Embolization, Therapeutic / adverse effects. Genital Diseases, Female / therapy. Urinary Tract / injuries. Urologic Diseases / etiology. Uterus / blood supply

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16635323.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


45. Brodsky JR, Kim DY, Jiang Z: Cervical lipoblastoma: case report, review of literature, and genetic analysis. Head Neck; 2007 Nov;29(11):1055-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical lipoblastoma: case report, review of literature, and genetic analysis.
  • BACKGROUND: Lipoblastoma is a rare, benign tumor of infants and children, usually occurring in the extremities and trunk, with only a few cases reported in the neck.
  • RESULTS: Complete surgical excision via a posterior cervical approach demonstrated irregular lobules of immature fat cells separated by a loose, myxoid connective tissue.
  • Histology and genetic analysis confirmed the diagnosis of lipoblastoma.
  • CONCLUSION: Cervical lipoblastoma is rare, and typically presents as an asymptomatic, painless mass, rarely causing airway obstruction or nerve compression.
  • MRI can be helpful in identifying the lipomatous nature of the mass, but the findings can be inconsistent due to variable maturity of fat cells and the mesenchymal content of the tumor.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Lipoma / diagnosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427967.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


46. Roijer E, de Bruijn HW, Dahlén U, ten Hoor K, Lundin M, Nilsson K, Soderstrom K, Nilsson O: Squamous cell carcinoma antigen isoforms in serum from cervical cancer patients. Tumour Biol; 2006;27(3):142-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma antigen isoforms in serum from cervical cancer patients.
  • SCCA isoforms were determined before therapy and in follow-up samples from patients with cervical cancer and in serum samples from healthy females.
  • Serum samples from patients with benign skin diseases (psoriasis and eczema) were also selected based on elevated SCCA levels.
  • The dominating serological form of SCCA was free SCCA2 both in healthy controls and in patients with cervical cancer.
  • Both SCCA1 and SCCA2 were elevated in serum from cervical cancer patients and followed the clinical course of the disease during therapy monitoring.
  • SCCA2 did not show improved tumor specificity as compared to SCCA1.
  • [MeSH-major] Antigens, Neoplasm / blood. Carcinoma, Squamous Cell / diagnosis. Enzyme-Linked Immunosorbent Assay. Serpins / blood. Uterine Cervical Neoplasms / diagnosis


47. Veras E, Sturgis EM, Luna MA: Heterotopic parathyroid inclusion in a cervical lymph node. Head Neck; 2007 Dec;29(12):1160-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterotopic parathyroid inclusion in a cervical lymph node.
  • Such findings may include benign epithelial inclusions, a second primary tumor, or chronic inflammatory diseases.
  • RESULTS: Histologic examination of the neck dissection specimen revealed benign parathyroid inclusions in the enlarged lymph node.
  • This case represents a unique example of heterotopic parathyroid inclusions in a cervical lymph node.
  • CONCLUSION: Parathyroid tissue should be included in the differential diagnosis of cervical intranodal epithelial inclusions.
  • [MeSH-minor] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Humans. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Laryngectomy. Male. Middle Aged. Neck Dissection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615563.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Ling J, Wiederkehr U, Cabiness S, Shroyer KR, Robinson JP: Application of flow cytometry for biomarker-based cervical cancer cells detection. Diagn Cytopathol; 2008 Feb;36(2):76-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of flow cytometry for biomarker-based cervical cancer cells detection.
  • The Pap test used for cervical cancer screening is subjective, labor-intensive, and has relatively low sensitivity and specificity for the detection of underlying clinically significant lesions.
  • The objective of this study is to develop a biomarker/flow cytometry-based approach for cervical cancer screening.
  • Immunofluorescence technology to quantify cervical cell expression of two biomarkers p16(INK4A) and Mcm5 was developed and evaluated by both microscopy and flow cytometry.
  • The capability of using biomarker/flow cytometry approach to detect rare-event dysplastic cells in a large background of benign epithelial and inflammatory cells was evaluated.
  • The results indicate that flow cytometry could detect 0.01% dysplastic cells in a background of normal cervical epithelial cells with the combination of the two biomarkers.
  • Thirty-two clinical specimens were used to test the biomarker/flow cytometry-based approach and the results were compared with the liquid-based cervical cytology.
  • The experiment yielded 100% sensitivity and 93% specificity with reference to the liquid-based cervical cytology.
  • This study indicates the promise of using multi-color fluorescence flow cytometry for biomarker-based cervical cancer screening.
  • This molecular-based, potentially high-throughput and automated method is expected to provide an alternative/auxiliary means of cervical cancer screening.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Cycle Proteins / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Flow Cytometry / methods. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biopsy. Cervix Uteri / metabolism. Cervix Uteri / pathology. Female. HeLa Cells. Humans. Mass Screening / methods. Sensitivity and Specificity


49. Yi KW, Song SH, Kim KA, Jung WY, Lee JK, Hur JY: Giant endocervical polyp mimicking cervical malignancy: primary excision and hysteroscopic resection. J Minim Invasive Gynecol; 2009 Jul-Aug;16(4):498-500
MedlinePlus Health Information. consumer health - Cervix Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant endocervical polyp mimicking cervical malignancy: primary excision and hysteroscopic resection.
  • Giant cervical polyps are characterized by an unusually large size and appear clinically as malignant.
  • Pelvic magnetic resonance imaging revealed a 12.6 x 8-cm solid tumor with internal papillary growth within the entire vaginal cavity.
  • The tumor base was suspected to have originated from the endocervix by a connecting stalk.
  • Primary excision of the tumor was performed via the vagina, and the remnant tissue was completely removed at hysteroscopic resection.
  • The final histopathologic findings confirmed a benign giant cervical polyp.
  • [MeSH-major] Polyps / pathology. Uterine Cervical Diseases / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm / blood. Female. Humans. Hysteroscopy. Serpins / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19573830.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  •  go-up   go-down


50. Chang CH, Tsai LC, Chen ST, Yuan CC, Hung MW, Hsieh BT, Chao PL, Tsai TH, Lee TW: Radioimmunotherapy and apoptotic induction on CK19-overexpressing human cervical carcinoma cells with Re-188-mAbCx-99. Anticancer Res; 2005 Jul-Aug;25(4):2719-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy and apoptotic induction on CK19-overexpressing human cervical carcinoma cells with Re-188-mAbCx-99.
  • The strategy and mechanism of radioimmunotherapy using Re-188-mAbCx-99 to Ck19 on human cervical carcinoma cells was investigated in this study.
  • RESULTS: A relatively high expression of Ck19 was found in all human cervical carcinoma cell lines (4- to 44-fold) and in tissue lysates (26.8- to 79-fold) from patients (31 out of 34) with cervical, endometrial or ovarian carcinomas compared with that of benign or normal control samples.
  • CONCLUSION: We suggest that an elevated Ck19 level is associated with disease stage in most patients with cervical cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Immunotoxins / pharmacology. Keratins / biosynthesis. Radioimmunotherapy / methods. Radioisotopes / pharmacology. Rhenium / pharmacology. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Antibody Specificity. Apoptosis / radiation effects. Cell Cycle Proteins / biosynthesis. Cell Growth Processes / radiation effects. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21. Female. HeLa Cells. Humans. Nucleosomes / metabolism. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Proto-Oncogene Proteins c-jun / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080517.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Immunotoxins; 0 / Nucleosomes; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-jun; 0 / Radioisotopes; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins; 7440-15-5 / Rhenium
  •  go-up   go-down


51. Zhou H, Liu Z, Liu C, Ma Q, Liu X, Jiang L, Wei F: Cervical chordoma in childhood without typical vertebral bony destruction: case report and review of the literature. Spine (Phila Pa 1976); 2009 Jun 15;34(14):E493-7
Genetic Alliance. consumer health - Chordoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical chordoma in childhood without typical vertebral bony destruction: case report and review of the literature.
  • OBJECTIVE: We present a giant cervical chordoma without typical vertebral bony destruction in an 11-year-old girl.
  • Cervical chordomas comprise only 3% to 7% of all chordomas.
  • To our knowledge, there is no case of cervical chordoma in a child, presenting without vertebral body involvement, in English literature.
  • METHODS: Discussion on the patient's clinical, radiologic history, and histopathologic diagnosis of the resected tumor, with a review of the relevant background literature.
  • RESULTS: We report the first case of cervical chordoma in a child without typical vertebral bony destruction, the diagnosis of which was difficult to confirm before and after operation.
  • CONCLUSION: Giant notochordal rest and benign notochordal cell tumors (BNCTs) need to be recognized for differential diagnosis of this atypical chordoma.
  • A long-term follow-up might be necessary for the diagnosis of this nontypical patient.
  • [MeSH-major] Chordoma / diagnosis. Spinal Neoplasms / diagnosis
  • [MeSH-minor] Cervical Vertebrae / radiography. Child. Female. Humans. Keratins / analysis. S100 Proteins / analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19525829.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 28
  •  go-up   go-down


52. Walid MS, Heaton RL: Case report of a cervical lipoleiomyoma with an incidentally discovered ovarian granulosa cell tumor - imaging and minimal-invasive surgical procedure. Ger Med Sci; 2010;8:Doc26
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of a cervical lipoleiomyoma with an incidentally discovered ovarian granulosa cell tumor - imaging and minimal-invasive surgical procedure.
  • Uterine lipoleiomyomas are rare benign tumors that mostly affect the uterine corpus.
  • We are reporting the imaging and operative procedure of a very rare case of a large lipoleiomyoma of the uterine cervix combined with an occult adult ovarian granulosa cell tumor.
  • [MeSH-major] Granulosa Cell Tumor / diagnosis. Leiomyoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2006 Jul;25(3):239-42 [16810060.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(6):439-40 [11874076.001]
  • [Cites] Br J Radiol. 1997 Oct;70(838):1068-70 [9404215.001]
  • [Cites] Abdom Imaging. 2000 Nov-Dec;25(6):655-7 [11029102.001]
  • [Cites] AJR Am J Roentgenol. 2001 Oct;177(4):856 [11566688.001]
  • (PMID = 21063471.001).
  • [ISSN] 1612-3174
  • [Journal-full-title] German medical science : GMS e-journal
  • [ISO-abbreviation] Ger Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2975263
  • [Keywords] NOTNLM ; granulosa cell tumor / lipomeiomyoma / total laparoscopic hysterectomy
  •  go-up   go-down


53. Lakshmi S, Rema P, Somanathan T: p16ink4a is a surrogate marker for high-risk and malignant cervical lesions in the presence of human papillomavirus. Pathobiology; 2009 May;76(3):141-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16ink4a is a surrogate marker for high-risk and malignant cervical lesions in the presence of human papillomavirus.
  • OBJECTIVE: To strengthen the role of high-risk human papillomaviruses (HPVs) in the development of cervical cancer, and the association between HPV and the cell cycle inhibitor gene p16ink4a in cervical carcinogenesis.
  • METHODS: In this study, the association between p16ink4a and the presence of HPV DNA in cervical lesions was investigated in a total of 177 cervical biopsies classified as benign (n = 42), low-grade squamous intraepithelial lesions (LSIL; n = 34), high-grade squamous intraepithelial lesions (HSIL; n = 48) and invasive cancer (n = 53).
  • RESULTS: No significant association was found between p16ink4a expression and HPV presence in benign and LSIL samples.
  • CONCLUSION: Immunohistochemical p16ink4a expression is associated with HPV infection in HSIL and cervical cancer, suggesting a role of p16 as a biomarker of HPV-associated cervical lesions.
  • [MeSH-major] Biomarkers, Tumor / genetics. Genes, p16. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / genetics. Cervical Intraepithelial Neoplasia / virology. Female. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization. Risk Factors

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19468254.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


54. Gong L, Zhang WD, Liu XY, Han XJ, Yao L, Zhu SJ, Lan M, Li YH, Zhang W: Clonal status and clinicopathological observation of cervical minimal deviation adenocarcinoma. Diagn Pathol; 2010;5:25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal status and clinicopathological observation of cervical minimal deviation adenocarcinoma.
  • BACKGROUND: Minimal deviation adenocarcinoma (MDA) of the uterine cervix is defined as an extremely well differentiated variant of cervical adenocarcinoma, with well-formed glands that resemble benign glands but show distinct nuclear anaplasia or evidence of stromal invasion.
  • Thus, MDA is difficult to differentiate from other cervical hyperplastic lesions.
  • Thus, our findings indicate that MDA is a true neoplasm but is not associated with high-risk HPV.
  • CONCLUSIONS: Diagnosis of MDA depends mainly on its clinical manifestations, the pathological feature that MDA glands are located deeper than the lower level of normal endocervical glands, and immunostaining.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Cell Differentiation. Chromosomes, Human, X. Receptors, Androgen / genetics. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / analysis. Case-Control Studies. Cell Proliferation. DNA, Viral / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization. Mosaicism. Neoplasm Invasiveness. Papillomaviridae / genetics. Polymerase Chain Reaction. Polymorphism, Genetic. Predictive Value of Tests. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Mol Pathol. 2001 Mar;10(1):24-33 [11277392.001]
  • [Cites] J Pathol. 2003 Dec;201(4):535-43 [14648656.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):962-72 [15143335.001]
  • [Cites] Am J Obstet Gynecol. 1975 Apr 1;121(7):971-5 [1115185.001]
  • [Cites] Biochim Biophys Acta. 1976 Oct 12;458(3):283-321 [1067873.001]
  • [Cites] Gynecol Oncol. 1980 Oct;10(2):125-33 [7461479.001]
  • [Cites] Pathology. 2008 Jun;40(4):392-5 [18446630.001]
  • [Cites] Am J Hum Genet. 1992 Dec;51(6):1229-39 [1281384.001]
  • [Cites] Mod Pathol. 1998 Jan;11(1):11-8 [9556417.001]
  • [Cites] Virchows Arch. 1998 Apr;432(4):315-22 [9565340.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jul;24(3):296-302 [15968208.001]
  • [Cites] Diagn Cytopathol. 2006 Feb;34(2):119-23 [16511847.001]
  • [Cites] Development. 1987 Feb;99(2):187-96 [3652995.001]
  • (PMID = 20416098.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / DNA, Viral; 0 / Receptors, Androgen
  • [Other-IDs] NLM/ PMC2877003
  •  go-up   go-down


55. Burduk PK, Dalke K, Szukalski J, Kaźmierczak W, Mierzwiński J: [Cervical sympathetic chain neurilemmoma--a case report]. Otolaryngol Pol; 2006;60(1):101-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cervical sympathetic chain neurilemmoma--a case report].
  • INTRODUCTION: Neurilemmoma is benign, slowly growing tumour that arise from nerves.
  • Cervical sympathetic chain neurilemmoma is rare.
  • The tumor was first noticed 6 month later, and it was slowly growing.
  • She underwent excision of the tumor through an incision parallel with the anterior border of the strenomastoid muscle.
  • RESULTS: Histology showed the tumour to be a neurilemmoma arising within the cervical sympathetic chain.
  • CONCLUSIONS: Neurilemmomas very rarely arise from the cervical sympathetic chain.
  • [MeSH-major] Ganglia, Sympathetic / pathology. Neurilemmoma / diagnosis. Neurilemmoma / surgery. Peripheral Nervous System Neoplasms / diagnosis. Peripheral Nervous System Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821553.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


56. Cuschieri K, Wentzensen N: Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2536-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.
  • Human papillomavirus (HPV) infection of the genital tract is very common and normally follows a benign clinical course; however, in an unfortunate minority of infected individuals, it can cause disease that sometimes leads to cancer.
  • It is accepted that HPV DNA testing has a role in the management of cervical disease both in a prevaccination and postvaccination era; however, to improve the specificity of this approach, there is a requirement to develop and validate tools/assays that can identify women at risk for progressive disease.
  • Currently, there is promising data indicating that HPV mRNA and p16 might play an important role in future cervical cancer screening scenarios.
  • METHODS: PubMed and OVID were interrogated with search terms "HPV RNA;" "HPV mRNA;" "HPV transcript-detection, testing, and methods;" "p16" AND "cervical cancer;" "p16" AND "CIN;" "p16" AND "histology"; "p16" AND "cytology;" "p16;" and "screening. "
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. RNA, Messenger / analysis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Mass Screening / methods. Precancerous Conditions / diagnosis. Precancerous Conditions / genetics. Precancerous Conditions / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2006 Nov 1;107(9):2307-13 [17029280.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):351-6 [17066437.001]
  • [Cites] Cancer. 2006 Dec 25;108(6):494-500 [17063495.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):58-66 [17186505.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):1-14 [17219448.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2435-8 [17294450.001]
  • [Cites] J Low Genit Tract Dis. 2007 Apr;11(2):98-104 [17415114.001]
  • [Cites] Cancer. 2007 Apr 25;111(2):83-92 [17334990.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1419-24 [17342094.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2599-605 [17473189.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):223-8 [17581402.001]
  • [Cites] Dis Markers. 2007;23(4):213-27 [17627057.001]
  • [Cites] J Med Virol. 2000 Oct;62(2):251-8 [11002256.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Mol Diagn. 2001 Jun;6(2):125-30 [11468697.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7874-87 [11753670.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7888-98 [11753671.001]
  • [Cites] Acta Cytol. 2002 Jan-Feb;46(1):25-9 [11843554.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] J Mol Diagn. 2002 May;4(2):97-102 [11986400.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2199-210 [12001118.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1948-52 [16103442.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):35-40 [15790434.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):578-84 [16139346.001]
  • [Cites] Cancer. 2005 Dec 25;105(6):461-7 [16116604.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1254-60 [16161049.001]
  • [Cites] Dis Markers. 2007;23(4):273-81 [17627062.001]
  • [Cites] Dis Markers. 2007;23(4):315-30 [17627065.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):871-6 [14712490.001]
  • [Cites] Lancet. 2007 Sep 8;370(9590):890-907 [17826171.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1579-88 [17942871.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2787-93 [17722112.001]
  • [Cites] Lancet. 2007 Nov 24;370(9601):1764-72 [17919718.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):132-7 [17468293.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Jan;6(1):83-95 [18267061.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):502-12 [18223479.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1389-99 [12409715.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):365-70 [12451568.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):56-63 [12499437.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Feb;25(1):8-11 [12630076.001]
  • [Cites] Cancer. 2003 Apr 25;99(2):89-96 [12704688.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):665-73 [12861062.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4212-22 [12912919.001]
  • [Cites] Acta Cytol. 2003 Jul-Aug;47(4):616-23 [12920756.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):201-8 [14529682.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):492-6 [15006929.001]
  • [Cites] J Med Virol. 2004 May;73(1):65-70 [15042650.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):173-80 [15098536.001]
  • [Cites] Cancer. 2004 Apr 25;102(2):100-8 [15098254.001]
  • [Cites] Cancer. 2004 Jun 25;102(3):142-9 [15211472.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3176-84 [15243079.001]
  • [Cites] J Med Virol. 2004 Sep;74(1):107-16 [15258976.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1355-60 [15298958.001]
  • [Cites] Diagn Cytopathol. 2004 Oct;31(4):235-42 [15452898.001]
  • [Cites] Hum Pathol. 1992 Feb;23(2):117-28 [1310950.001]
  • [Cites] J Virol Methods. 1991 Dec;35(3):305-13 [1667790.001]
  • [Cites] Int J Cancer. 1992 Jul 9;51(5):831-4 [1319412.001]
  • [Cites] Gynecol Oncol. 1995 Feb;56(2):239-44 [7896192.001]
  • [Cites] J Virol Methods. 1995 Jul;54(1):75-81 [7559859.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):610-5 [15378361.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):616-20 [15480761.001]
  • [Cites] Acta Cytol. 2004 Nov-Dec;48(6):771-82 [15581161.001]
  • [Cites] Diagn Cytopathol. 2005 Jan;32(1):21-4 [15584047.001]
  • [Cites] J Virol Methods. 2005 Mar;124(1-2):211-5 [15664071.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):267-73 [15492761.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):367-72 [15734959.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):973-6 [15645423.001]
  • [Cites] J Clin Pathol. 2005 May;58(5):525-34 [15858126.001]
  • [Cites] Zentralbl Gynakol. 2005 Jun;127(3):140-5 [15915391.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):908-15 [15943992.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9 [16030305.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):347-53 [16445657.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):791-6 [16287075.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):384-91 [16415792.001]
  • [Cites] Clin Sci (Lond). 2006 May;110(5):525-41 [16597322.001]
  • [Cites] J Clin Microbiol. 2006 Apr;44(4):1310-7 [16597856.001]
  • [Cites] Cancer. 2006 Apr 25;108(2):119-23 [16411180.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1102-7 [16570279.001]
  • [Cites] Br J Dermatol. 2006 Jul;155(1):129-36 [16792764.001]
  • [Cites] J Clin Pathol. 2006 Aug;59(8):827-30 [16467166.001]
  • [Cites] J Virol Methods. 2006 Oct;137(1):58-62 [16828171.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):62-6 [16494930.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):18-20 [16919709.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1017-28 [16679355.001]
  • (PMID = 18842994.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010124-14
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / RNA, Messenger
  • [Number-of-references] 89
  • [Other-IDs] NLM/ NIHMS212843; NLM/ PMC2900792
  •  go-up   go-down


57. Wang W, Kong L, Dong R, Zhao H, Ma Y, Lu Y: Osteoma in the upper cervical spine with spinal cord compression. Eur Spine J; 2006 Oct;15 Suppl 5:616-20
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoma in the upper cervical spine with spinal cord compression.
  • Osteoma is a common benign tumor.
  • The authors reported two rare cases of intra-canal osteoma of the upper cervical spine with cord compression.
  • On systemic examination and rontgenographic study, these two cases were found to have bone tumor in the upper cervical canal.
  • Surgical interventions were performed, one with an en bloc excision, the other with a subtotal excision.
  • The pathological study demonstrated a diagnosis of osteoma.
  • [MeSH-major] Cervical Vertebrae. Decompression, Surgical. Osteoma / complications. Spinal Cord Compression / etiology. Spinal Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spine (Phila Pa 1976). 2004 Feb 15;29(4):E75-8 [15094549.001]
  • [Cites] Neurochirurgie. 1980;26(2):165-70 [7412981.001]
  • [Cites] Vopr Onkol. 1986;32(9):24-8 [3765518.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):182-5 [9442522.001]
  • [Cites] J Bone Joint Surg Am. 1996 Aug;78(8):1172-80 [8753709.001]
  • [Cites] Spine (Phila Pa 1976). 1996 Jul 15;21(14):1687-93 [8839473.001]
  • [Cites] Chir Organi Mov. 1993 Apr-Jun;78(2):65-75 [8344077.001]
  • (PMID = 16649125.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 14
  • [Other-IDs] NLM/ PMC1602193
  •  go-up   go-down


58. Sanati S, Huettner P, Ylagan LR: Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol; 2010 Jan;29(1):79-87
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens.
  • Our purpose was to evaluate the sensitivity, specificity, and predictive value of ProExC in dysplastic squamous and glandular lesions of the cervix.
  • ProExC had sensitivity, specificity, and positive and negative predictive value of 89%, 100%, 100%, and 82%, respectively, for distinguishing high-grade squamous intraepithelial lesion from squamous metaplasia, and 93%, 100%, 100%, and 98%, respectively, for distinguishing adenocarcinoma in situ from reactive benign endocervix.
  • ProExC is a valuable marker for distinguishing dysplastic squamous and endocervical lesions of the cervix from squamous metaplasia in histologic sections.
  • ProExC may eventually be used in conjunction with morphologic and human papillomavirus evaluation for better classification of indeterminate cervical lesions in Papanicolaou smears.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervical Intraepithelial Neoplasia / diagnosis. Immunoenzyme Techniques. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Female. Humans. Middle Aged. Minichromosome Maintenance Complex Component 2. Nuclear Proteins / biosynthesis. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952938.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


59. Combalia Aleu A, Popescu D, Pomes J, Palacin A: Long-standing pain in a 25-year-old patient with a non-diagnosed cervical osteoblastoma: a case report. Arch Orthop Trauma Surg; 2008 Jun;128(6):567-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-standing pain in a 25-year-old patient with a non-diagnosed cervical osteoblastoma: a case report.
  • Benign osteoblastomas are infrequent tumors, representing less than 1% of all bone tumors.
  • The spinal location accounts for 40-50% of all osteoblastomas from which only 20% are located in the cervical spine.
  • We present a case report of a young male that due to the lack of specific symptoms was diagnosed of a cervical osteoblastoma 14 months after the first symptoms.
  • The tumor was located in the right C7 pedicle.
  • We then operated, resected the tumor and a posterior C6-T1 bilateral instrumentation was performed to stabilize the spine.
  • Nowadays, this delay in diagnosis may be avoided by the routine use of MRI or CT for unspecific cervical symptoms.
  • The treatment of this lesion is the complete surgical resection based on a correct preoperative planning with CT and MRI in order to define precisely the location, size and extension of the tumor.
  • [MeSH-major] Cervical Vertebrae. Osteoblastoma / diagnosis. Spinal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641905.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. McCluggage WG: Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology; 2007 Feb;39(1):97-111
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry as a diagnostic aid in cervical pathology.
  • As with biopsies from other sites in the female genital tract, immunohistochemistry is now being increasingly used in cervical pathology as an aid to diagnosis.
  • In this review, I discuss applications of immunohistochemistry in diagnostic cervical pathology with a particular focus on recent developments.
  • Although much of this review focuses on glandular lesions, the value of markers, such as MIB1 and p16, in the assessment of pre-invasive cervical squamous lesions is discussed.
  • In the broad field of cervical glandular lesions, topics covered include: the value of markers such as MIB1, p16 and bcl-2 in distinguishing adenocarcinoma in situ and glandular dysplasia from benign mimics; markers of mesonephric lesions, including CD10; markers of value in the diagnosis of minimal deviation adenocarcinoma, such as HIK1083; markers of value in distinguishing metastatic cervical adenocarcinoma in the ovary from primary ovarian endometrioid or mucinous adenocarcinoma.
  • Rarely ectopic prostatic tissue occurs in the cervix, which can be confirmed by positive staining with prostatic markers.
  • A panel of markers, comprising oestrogen receptor, vimentin, monoclonal carcinoembryonic antigen and p16, is of value in distinguishing between a cervical adenocarcinoma and an endometrial adenocarcinoma of endometrioid type.
  • Markers of use in the diagnosis of cervical neuroendocrine neoplasms, including small cell and large cell neuroendocrine carcinoma, are discussed.
  • It is stressed that small cell neuroendocrine carcinomas may be negative with most of the commonly used neuroendocrine markers and this does not preclude the diagnosis. p63, a useful marker of squamous neoplasms within the cervix, is of value in distinguishing small cell neuroendocrine carcinoma (p63 negative) from small cell squamous carcinoma (p63 positive) and in confirming that a poorly differentiated carcinoma is squamous in type.
  • [MeSH-major] Biomarkers, Tumor / analysis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365826.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 104
  •  go-up   go-down


61. Thompson LD, Karamurzin Y, Wu ML, Kim JH: Solitary fibrous tumor of the larynx. Head Neck Pathol; 2008 Jun;2(2):67-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the larynx.
  • BACKGROUND: True mesenchymal, non-cartilaginous neoplasms of the larynx are rare.
  • Extrapleural solitary fibrous tumor (SFT) is a localized neoplasm characterized by proliferation of thin-walled vessels and collagen-producing cells and is considered within the "hemangiopericytoma-solitary fibrous tumor" spectrum.
  • There were no cervical deformities on physical exam.
  • A cellular, spindle cell neoplasm was arranged in loose fascicles, associated with heavy collagen fiber deposition.
  • These findings confirmed a diagnosis of extraplural solitary fibrous tumor.
  • CONCLUSIONS: The characteristic histologic pattern of solitary fibrous tumor can be noted in extrapulmonary locations.
  • Development in the larynx is uncommon, but the tumor presents as a polypoid mass with characteristic histologic and immunophenotypic features.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Solitary Fibrous Tumors / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Disease-Free Survival. Humans. Male. Middle Aged. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngol Head Neck Surg. 2005 Jul;133(1):163-5 [16025074.001]
  • [Cites] Arch Pathol Lab Med. 2006 Feb;130(2):213-6 [16454566.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 May;134(5):880-2 [16647552.001]
  • [Cites] Auris Nasus Larynx. 2007 Sep;34(3):405-8 [17337142.001]
  • [Cites] Mod Pathol. 1999 Nov;12(11):1034-42 [10574600.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1464-73 [10667425.001]
  • [Cites] Virchows Arch. 2000 Sep;437(3):248-55 [11037344.001]
  • [Cites] Laryngoscope. 2001 Jul;111(7):1197-202 [11568541.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):153-70 [11812937.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1057-68 [11920476.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):737-49 [12766577.001]
  • [Cites] Laryngoscope. 2003 May;113(5):783-90 [12792311.001]
  • [Cites] Cancer. 1979 Feb;43(2):627-35 [421185.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] J Laryngol Otol. 1993 Mar;107(3):252-6 [8509708.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):992-8 [7522416.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1257-66 [7573687.001]
  • [Cites] J Pathol. 1997 Apr;181(4):362-7 [9196431.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jun;111(2):169-71 [10347558.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Apr;262(4):286-8 [15170575.001]
  • [Cites] Mod Pathol. 1997 Oct;10(10):1028-37 [9346183.001]
  • [Cites] Mod Pathol. 1997 Dec;10(12):1194-200 [9436963.001]
  • [Cites] Histopathology. 1997 Dec;31(6):568-76 [9447390.001]
  • [Cites] J Laryngol Otol. 1998 Mar;112(3):286-9 [9624382.001]
  • (PMID = 20614325.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807554
  • [Keywords] NOTNLM ; Benign neoplasm / CD34 / Fibroma / Hemangiopericytoma / Immunohistochemistry / Larynx / Mesenchymal tumor / Prognosis / Solitary fibrous tumor / Spindle cell squamous cell carcinoma / Surgery / True vocal cord / bcl-2
  •  go-up   go-down


62. Kalyanasundaram K, Ganesan R, Perunovic B, McCluggage WG: Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int J Surg Pathol; 2010 Apr;18(2):138-43
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis.
  • Endometrial carcinomas, particularly of endometrioid type, can invade the myometrium or cervix without eliciting a stromal desmoplastic or inflammatory response and have been referred to as diffusely infiltrating endometrial carcinomas.
  • The neoplasms consisted of 12 endometrioid carcinomas, 1 mixed endometrioid and clear cell carcinoma, and 1 serous carcinoma.
  • Seven cases exhibited cervical stromal involvement and in 2 there was involvement of both ovaries in a similar pattern.
  • Several of the cases were seen in consultation and the pattern of infiltration raised a number of differential diagnoses, both benign and malignant, depending on the site of tumor involvement, including adenomyosis, adenomyoma, primary endocervical glandular lesions, cervical mesonephric remnants, endometriosis or tuboendometrioid metaplasia, and ovarian cortical inclusion cysts.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnostic Errors / prevention & control. Female. Humans. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Stromal Cells / pathology


63. Qiao X, Bhuiya TA, Spitzer M: Differentiating high-grade cervical intraepithelial lesion from atrophy in postmenopausal women using Ki-67, cyclin E, and p16 immunohistochemical analysis. J Low Genit Tract Dis; 2005 Apr;9(2):100-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiating high-grade cervical intraepithelial lesion from atrophy in postmenopausal women using Ki-67, cyclin E, and p16 immunohistochemical analysis.
  • OBJECTIVE: In postmenopausal women, differentiating high-grade cervical intraepithelial neoplasia (CIN 2,3) from atrophic uterine cervical squamous epithelium histologically may pose a diagnostic challenge.
  • In this study, we compared the staining features of Ki-67, cyclin E, and p16 in cervix specimens from postmenopausal women to distinguish CIN 2,3 from atrophy.
  • METHODS: Twenty-six formalin-fixed paraffin-embedded archival cervical specimens (4 biopsy, 8 laser cone, and 14 total hysterectomy samples) were selected from 25 women 50 to 80 years of age (mean = 64 years).
  • In coexistent CIN 2,3 and atrophy cases, the three-antibody panel clearly demarcated the transition from benign to neoplastic epithelia.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Atrophy. Cyclin E / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Postmenopause / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870531.001).
  • [ISSN] 1089-2591
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen
  •  go-up   go-down


64. Ferris RL, Xi L, Raja S, Hunt JL, Wang J, Gooding WE, Kelly L, Ching J, Luketich JD, Godfrey TE: Molecular staging of cervical lymph nodes in squamous cell carcinoma of the head and neck. Cancer Res; 2005 Mar 15;65(6):2147-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular staging of cervical lymph nodes in squamous cell carcinoma of the head and neck.
  • Clinical staging of cervical lymph nodes from patients with squamous cell carcinoma of the head and neck (SCCHN) has only 50% accuracy compared with definitive pathologic assessment.
  • We used quantitative reverse transcription-PCR (QRT-PCR) to screen 40 potential markers for their ability to detect SCCHN metastases to cervical lymph nodes.
  • Seven markers were identified with good characteristics for identifying metastatic disease, and these were validated using a set of 26 primary tumors, 19 histologically positive lymph nodes, and 21 benign nodes from patients without cancer.
  • Four markers discriminated between positive and benign nodes with accuracy >97% but only one marker, pemphigus vulgaris antigen (PVA), discriminated with 100% accuracy in both the observed data and a statistical bootstrap analysis.
  • The automated analysis with PVA provided perfect discrimination between histologically positive and benign lymph nodes and correctly identified two lymph nodes with micrometastatic tumor deposits.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Lymph Nodes / pathology. Reverse Transcriptase Polymerase Chain Reaction / methods. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781625.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA90665-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


65. Wang CP, Chang YL, Ko JY, Cheng CH, Yeh CF, Lou PJ: Desmoid tumor of the head and neck. Head Neck; 2006 Nov;28(11):1008-13
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoid tumor of the head and neck.
  • BACKGROUND: [corrected] Desmoid tumors are rare benign tumors but have a tendency toward local recurrence after resection because of their infiltrative growth and frequent entrapment of vital structures in the head and neck region.
  • METHODS: Twenty-four patients (9 male and 15 female; median age, 33 years; range, 0-66 years) with a desmoid tumor of the head and neck (neck, 15 patients; head, 9 patients) treated from 1990 to 2004 were retrospectively analyzed.
  • In the neck, 8 tumors were around the superficial layer of deep cervical fascia, whereas 4 tumors of the neck involved the prevertebral fascia and 2 involved brachial plexus.
  • RESULTS: Twenty patients received complete resection of the tumor, but the section margin was positive in 8 patients, of which 6 patients remained free of disease in a period of 13 to 105 months.
  • Two patients underwent partial resection of the tumor because of brachial plexus involvement.
  • The hypopharygneal tumor in a newborn had spontaneously complete regression, and tracheostomy was closed at the age of 6 years.
  • One patient remained with stable disease for 14 months after biopsy of the tumor without excision.
  • Surgical resection of the tumor with close observation is suggested even if the section margin is positive.
  • If a desmoid tumor cannot be removed grossly, regression or arrested growth of the remaining tumor is expected.
  • Radiotherapy might be reserved for a growing tumor.
  • [MeSH-major] Fibromatosis, Aggressive / surgery. Head and Neck Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16983695.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Jones EE, Wells SI: Cervical cancer and human papillomaviruses: inactivation of retinoblastoma and other tumor suppressor pathways. Curr Mol Med; 2006 Nov;6(7):795-808
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical cancer and human papillomaviruses: inactivation of retinoblastoma and other tumor suppressor pathways.
  • Infection with human papillomaviruses (HPVs) is a major public health burden worldwide and is associated with benign and malignant lesions of the skin and genital tract.
  • HPV causes cervical cancer, which represents the second most prevalent cancer in women worldwide.
  • [MeSH-major] Cell Transformation, Neoplastic. Cell Transformation, Viral. Papillomaviridae / physiology. Papillomavirus Infections / metabolism. Retinoblastoma Protein / physiology. Signal Transduction. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Animals. Female. Genes, Tumor Suppressor / physiology. Humans

  • Genetic Alliance. consumer health - Retinoblastoma.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100604.001).
  • [ISSN] 1566-5240
  • [Journal-full-title] Current molecular medicine
  • [ISO-abbreviation] Curr. Mol. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102357
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Retinoblastoma Protein
  • [Number-of-references] 234
  •  go-up   go-down


67. Muzumdar D, Ventureyra EC: Tonsillar herniation and cervical syringomyelia in association with posterior fossa tumors in children: a case-based update. Childs Nerv Syst; 2006 May;22(5):454-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tonsillar herniation and cervical syringomyelia in association with posterior fossa tumors in children: a case-based update.
  • The symptomatology is predominantly directed towards the tumor.
  • CASE REPORT: We describe a case of a pilocytic astrocytoma of the cerebellum in a 13-year-old girl who presented with clinical features of progressively worsening raised intracranial pressure and secondary tonsillar herniation and cervical syringomyelia.
  • Magnetic resonance (MR) imaging showed a large midline inhomogenously enhancing vermian tumor causing moderate obstructive hydrocephalus.
  • The tumor was resected through a suboccipital craniectomy.
  • At follow-up after 3 months, MR imaging demonstrated total resolution of tonsillar herniation and cervical syringomyelia.
  • CONCLUSIONS: The occurrence of tonsillar herniation and syringomyelia in association with a slow growing benign tumor like pilocytic astrocytoma of the cerebellum is uncommon.
  • Surgical extirpation of the tumor restores the normal cerebrospinal fluid circulation at the foramen magnum and produces an excellent outcome.
  • [MeSH-major] Astrocytoma. Hernia / etiology. Infratentorial Neoplasms / complications. Palatine Tonsil / pathology. Syringomyelia / etiology

  • Genetic Alliance. consumer health - Syringomyelia.
  • MedlinePlus Health Information. consumer health - Hernia.
  • MedlinePlus Health Information. consumer health - Syringomyelia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 1987 Jan-Feb;8(1):11-7 [3101451.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Aug;37(8):624-6 [9301200.001]
  • [Cites] Neurosurgery. 1994 Aug;35(2):214-23; discussion 223-4 [7969828.001]
  • [Cites] Br J Neurosurg. 1996 Aug;10(4):409-11 [8864510.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(3):293-301; discussion 301-2 [10819260.001]
  • [Cites] Br J Neurosurg. 1989;3(6):669-74 [2627286.001]
  • [Cites] Clin Neuropathol. 1998 Nov-Dec;17(6):305-10 [9832257.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Dec;33(12):833-5 [7512230.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Jul 15;28(14):E279-83 [12865864.001]
  • [Cites] Neurol India. 2000 Mar;48(1):81-3 [10751821.001]
  • [Cites] AJNR Am J Neuroradiol. 1988 Sep;9(5):867-73 [3140628.001]
  • [Cites] Surg Neurol. 1993 Dec;40(6):512-5 [8235977.001]
  • [Cites] Neurochirurgie. 1979 Apr 19-21;25 Suppl 1:9-22 [481676.001]
  • [Cites] J Neurol Sci. 2004 May 15;220(1-2):3-21 [15140600.001]
  • [Cites] Clin Neurosurg. 1958;6:131-40 [13826542.001]
  • [Cites] J Neurosurg. 1998 Jun;88(6):962-8 [9609289.001]
  • [Cites] Neurosurgery. 1999 May;44(5):1065-75; discussion 1075-6 [10232540.001]
  • [Cites] Radiology. 1991 Feb;178(2):467-74 [1987610.001]
  • [Cites] Surg Neurol. 1985 Mar;23 (3):291-4 [3975813.001]
  • [Cites] Surg Neurol. 1987 Feb;27(2):187-90 [3810449.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1977 Jan;40(1):80-8 [845611.001]
  • [Cites] J Neurol. 1980;222(4):219-25 [6154780.001]
  • [Cites] Neurosurgery. 1997 Nov;41(5):1102-10 [9361064.001]
  • [Cites] Acta Neurochir (Wien). 2002 Jul;144(7):741-2 [12181709.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 Apr;44(4):273-84 [7241155.001]
  • [Cites] Acta Neurochir (Wien). 1995;137(1-2):38-43 [8748866.001]
  • [Cites] Neurosurgery. 1991 May;28(5):639-45 [1876240.001]
  • [Cites] AJNR Am J Neuroradiol. 1986 Jul-Aug;7(4):571-9 [3088935.001]
  • [Cites] Neuroradiology. 1990;32(5):371-91 [2259432.001]
  • [Cites] Acta Neurochir (Wien). 2002 Apr;144(4):385-8 [12021887.001]
  • [Cites] J Neurosurg. 1995 May;82(5):802-12 [7714606.001]
  • [Cites] Neurol Res. 1986 Sep;8(3):130-45 [2877406.001]
  • [Cites] J Neurosurg. 1990 Jan;72(1):133-8 [2294173.001]
  • [Cites] Neurol India. 2001 Sep;49(3):323 [11593259.001]
  • [Cites] Br J Neurosurg. 1998 Feb;12(1):33-6 [11013645.001]
  • [Cites] Br J Neurosurg. 2004 Feb;18(1):70-1 [15040721.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 May;30(5):324-8 [1699148.001]
  • [Cites] J Neurosurg. 1994 Jan;80(1):3-15 [8271018.001]
  • [Cites] Lancet. 1970 Jun 6;1(7658):1234 [4192419.001]
  • [Cites] Neuroradiology. 1996 Aug;38(6):529-31 [8880711.001]
  • [Cites] Lancet. 1972 Oct 14;2(7781):799-801 [4116236.001]
  • [Cites] Neurosurgery. 1995 Dec;37(6):1069-74 [8584146.001]
  • [Cites] Surg Neurol. 1995 May;43(5):470-5; discussion 475-7 [7660286.001]
  • [Cites] Eur Neurol. 1974;12(2):116-27 [4139014.001]
  • [Cites] Acta Pathol Jpn. 1992 Jan;42(1):25-34 [1557985.001]
  • [Cites] AJNR Am J Neuroradiol. 1983 Jan-Feb;4(1):73-8 [6402905.001]
  • [Cites] J Neurol. 1982;227(2):67-73 [6180141.001]
  • [Cites] J Neurosurg. 1997 May;86(5):907 [9126912.001]
  • (PMID = 16397818.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


68. Zhang F, Ni B, Zhao L, Chen H, Li S, Zhou F, Yang J, Tsai N: Desmoplastic fibroma of the cervical spine: case report and review of the literature. Spine (Phila Pa 1976); 2010 Jun 15;35(14):E667-71
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic fibroma of the cervical spine: case report and review of the literature.
  • OBJECTIVE: To present a rare case of desmoplastic fibroma (DF) in the cervical spine and discuss the diagnosis and treatment of this disorder.
  • SUMMARY OF BACKGROUND DATA: DF is an extremely rare primary tumor of bone, especially in cervical spine.
  • It is a benign but locally aggressive tumor of the connective tissue.
  • METHODS: We report on a 70-year-old woman with a DF of the fourth and fifth cervical vertebrae.
  • After radiologic evaluation, a mass lesion was found on the fourth and fifth cervical vertebral bodies.
  • A 2-level corpectomy with wide marginal resection of the tumor was performed through the anterior approach, and the histopathologic examination yielded the diagnosis of DF.
  • CONCLUSION: Patients with DF of the cervical spine may present with the arm and neck pain mimicking cervical disc disease.
  • High index of suspicion by the clinicians must be practiced to make the appropriate diagnosis, and histologic confirmation of the diagnosis is essential.
  • [MeSH-major] Cervical Vertebrae. Fibroma, Desmoplastic / surgery. Spinal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505566.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


69. Barroeta JE, Pasha TL, Acs G, Zhang PJ: Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement. Int J Gynecol Pathol; 2007 Jan;26(1):76-82
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement.
  • To evaluate and compare the immunophenotype of endocervical and endometrial stromal cells and to asses its potential application in tumor localization.
  • Paraffin sections of benign endocervix (n = 24), benign endometrium (n = 33), endocervical adenocarcinoma (n = 9), endometrial carcinoma (n = 13), and endometrial hyperplasia (n = 16) were stained with antibodies to CD10, Wilms Tumor-1, CD34, smooth muscle actin, and factor XIIIa by immunohistochemistry.
  • In 16 cases, lower uterine segment was also available.
  • Endocervical stromal cells (ECSC) in either benign or malignant cervical epithelial lesions were predominantly CD34/CD10 (CD34 dominant immunophenotype).
  • Endometrial stromal cells (EMSCs) in either benign or malignant epithelial lesions were primarily CD34/CD10 (CD10 dominant immunophenotype).
  • Expression of Wilms Tumor-1 was decreased in EMSC of the EMCA when compared to their counterpart in endometrial hyperplasia.
  • The immunophenotypes of the ECSC and EMSC overlapped in the lower uterine segment.
  • The pattern of CD34 and CD10 immunostaining in stromal cells might be helpful in determining tumor involvement in uterine and cervical sites.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Stromal Cells / metabolism. Stromal Cells / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197901.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Kim HC, Yoon DY, Chang SK, Han H, Oh SJ, Kim JH, Rho YS, Ahn HY, Kim KH, Shin YC: Small atypical cervical nodes detected on sonography in patients with squamous cell carcinoma of the head and neck: probability of metastasis. J Ultrasound Med; 2010 Apr;29(4):531-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small atypical cervical nodes detected on sonography in patients with squamous cell carcinoma of the head and neck: probability of metastasis.
  • OBJECTIVE: The purpose of this study was to assess the probability of metastasis of small atypical cervical lymph nodes detected on sonography in patients with squamous cell carcinoma (SCC) of the head and neck.
  • Each lymph node was classified by using a 4-point scale: 1, definitely benign; 2, indeterminate (small [short-axis diameter <10 mm for levels I and II and <7 mm for levels III-VI] atypical node); 3, definitely metastatic; and 4, large (>3-cm) metastatic.
  • RESULTS: Small atypical nodes were found on sonography in 63 cervical levels of 48 patients, of which 18 (28.6%) were proved to have metastatic nodes.
  • The probability of metastasis was significantly higher with than without a large (>3-cm) ipsilateral metastatic node (0.50 versus 0.20; P = .038) and marginally higher with than without an ipsilateral metastatic node (0.41 versus 0.16; P = .061) but not significantly associated with the T stage of the primary tumor (P = .238) or the presence of an ipsilateral tumor (P = .904).
  • CONCLUSIONS: Metastasis was encountered in about 30% of small atypical cervical nodes on sonography in patients with SCC of the head and neck.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Lymphatic Metastasis / ultrasonography


71. George B, Archilli M, Cornelius JF: Bone tumors at the cranio-cervical junction. Surgical management and results from a series of 41 cases. Acta Neurochir (Wien); 2006 Jul;148(7):741-9; discussion 749
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone tumors at the cranio-cervical junction. Surgical management and results from a series of 41 cases.
  • BACKGROUND: Bone tumors located at the cranio-cervical junction (CCJ)are rare.
  • METHODS: Forty-one patients presenting a bone tumor (26 benign and 15 malignant tumors), excluding chordomas, located at the CCJ (including lower third of the clivus, C1 and C2) were observed over 20 years from 1981 to 2001.
  • Vertebral angiography was rarely performed (N=9) and mostly when the diagnosis was doubtful.
  • In some cases the diagnosis was clear but in others, imaging studies showed destructive lesions suggesting a malignancy, which sometimes required a biopsy (N=4).
  • No recurrence in the group of benign tumors was seen during an average follow-up of 6 years (from 2 to 11 years).
  • Confusion between benign and malignant tumor or pseudo tumors must be avoided, sometimes requiring a biopsy.
  • [MeSH-major] Axis, Cervical Vertebra / surgery. Bone Neoplasms / surgery. Cervical Atlas / surgery. Neurosurgical Procedures / methods. Occipital Bone / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Cerebral Angiography. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neck Pain / etiology. Neck Pain / physiopathology. Neck Pain / surgery. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiography. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Retrospective Studies. Spinal Fusion. Tomography, X-Ray Computed. Treatment Outcome. Vertebral Artery / anatomy & histology. Vertebral Artery / pathology. Vertebral Artery / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708168.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


72. Jonathan A, Rajshekhar V, Chacko G: Chondromyxoid fibroma of the seventh cervical vertebra. Neurol India; 2008 Jan-Mar;56(1):84-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondromyxoid fibroma of the seventh cervical vertebra.
  • Chondromyxoid fibroma is a rare benign bone tumor representing less than 0.5% of all bone tumors.
  • A presumptive diagnosis of a bony tumor such as an aneurysmal bone cyst or a giant cell tumor involving the seventh vertebral body was made on plain X-rays, MRI and bone scan.
  • The histological diagnosis was chondromyxoid fibroma.
  • On eight years' follow-up, CT scan showed no progression of the tumor with good alignment and fusion of the graft at the site of the corpectomy.
  • [MeSH-major] Bone Neoplasms / complications. Bone Neoplasms / pathology. Cervical Vertebrae / pathology. Chondromatosis / complications. Fibroma / complications. Fibroma / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310848.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


73. Wang SS, Dasgupta A, Sherman ME, Walker JL, Gold MA, Zuna R, Sakoda L, Wacholder S, Schiffman M, Baker CC: Towards improved biomarker studies of cervical neoplasia: effects of precolposcopic procedures on gene expression patterns. Diagn Mol Pathol; 2005 Jun;14(2):59-64
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Towards improved biomarker studies of cervical neoplasia: effects of precolposcopic procedures on gene expression patterns.
  • Among tumor sites, cervical cancer offers an ideal model for investigating differences in gene expression associated with transitions from normal to precancer and invasion to cancer.
  • To evaluate the validity of assessing gene expression in cervical tissues acquired in a clinical setting, we investigated whether standard procedures, namely the application of acetic acid and/or Lugol's iodine, employed for the visualization of colposcopically directed biopsies, altered patterns in oligonucleotide (oligo) arrays.
  • We compared microarray profiles from six women, each with three adjacent tissue samples removed from benign hysterectomy specimens and treated as follows: immediately frozen, acetic acid application only, acetic acid, and Lugol's iodine.
  • Upon adjustment for multiple comparisons using both the Holm's and Hochberg's procedures as well as the False Discovery Rate (Benjamini-Hochberg and Benjamini-Yeuketili [BY]), we failed to identify genes differentially expressed and conclude that standard precolposcopic procedures do not substantially affect the overall gene expression patterns in the normal cervix.
  • [MeSH-major] Biomarkers, Tumor / genetics. Biomarkers, Tumor / standards. Cervix Uteri / metabolism. Colposcopy. Gene Expression Profiling. Uterine Cervical Neoplasms / diagnosis


74. Cheah PL, Looi LM: Significance of Bcl-2 and Bax proteins in cervical carcinogenesis: an immunohistochemical study in squamous cell carcinoma and squamous intraepithelial lesions. Malays J Pathol; 2006 Jun;28(1):1-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of Bcl-2 and Bax proteins in cervical carcinogenesis: an immunohistochemical study in squamous cell carcinoma and squamous intraepithelial lesions.
  • Sixteen low grade (LSIL), 22 high grade (HSIL) squamous intraepithelial lesions, 28 invasive (13 stage I and 15 stage II-IV) squamous cell carcinoma (SCC) and 15 benign cervices were immunohistochemically studied for involvement of Bcl-2 and Bax proteins in cervical carcinogenesis.
  • Bcl-2 was upregulated (p < 0.05) in HSIL and Bax in SCC when compared with benign cervical squamous epithelium.
  • Bcl-2 expression was confined to the lower third of the epithelium in the benign cervices and LSIL.
  • SCCs showed "diffuse" (evenly distributed) or "basal" (intensified staining around the periphery of the invading tumour nests) expression of Bcl-2.
  • Benign cervical squamous epithelium, LSIL, HSIL and SCC showed a generally diffuse Bax expression.
  • Thus, Bcl-2 and Bax appeared to be upregulated at different stages of cervical carcinogenesis, Bcl-2 in HSIL and Bax after invasion.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Uterine Cervical Neoplasms / metabolism. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694953.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


75. Takatani T, Arai H, Fujii K, Yasuda T, Kohno Y: A posterior fossa lipoma extending into the cervical spine and subcutaneous space via a cranium bifidum. Brain Dev; 2008 Oct;30(9):603-5
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A posterior fossa lipoma extending into the cervical spine and subcutaneous space via a cranium bifidum.
  • The patient had a subcutaneous tumor of the posterior neck at birth, which was gradually growing and subsequently accompanied by gait disturbance and ataxia.
  • MR imaging revealed the intracranial lipoma in the posterior fossa extending into the cervical spinal canal and subcutaneous space via a cranium bifidum.
  • Although intracranial lipomas are usually benign and asymptomatic, early detection of them is quite critical, and body weight control may help to prevent their progression.
  • [MeSH-major] Cervical Vertebrae. Cranial Fossa, Posterior / pathology. Lipoma / pathology. Spinal Cord Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18378416.001).
  • [ISSN] 0387-7604
  • [Journal-full-title] Brain & development
  • [ISO-abbreviation] Brain Dev.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


76. Hariri J, Øster A: The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol; 2007 Jul;26(3):223-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix.
  • The immunohistochemical expression of p16 in formalin-fixed and paraffin-embedded histological sections was evaluated in a retrospective study comprising a low-grade group of 100 cases of cervical intraepithelial neoplasia (CIN) 1, a high-grade group of 50 cases of CIN 2 to 3, and a benign group of 50 cases of normal tissue or benign lesions in the uterine cervix.
  • Positive reaction for p16 was detected in all cases in the high-grade group and in only 3 cases in the benign group.
  • All but one of these p16 negative cases in the low-grade group had a benign or normal outcome.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cervical Intraepithelial Neoplasia / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581402.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


77. Matsumura Y: [Thoracoscopic surgery of mediastinal tumor]. Kyobu Geka; 2010 Jul;63(8 Suppl):724-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thoracoscopic surgery of mediastinal tumor].
  • So that VATS to the anterior MTs needs some sternal lifting devices to get working space with appropriate combinations of intercostal, infrasternal and cervical approaches under supine position.
  • Benign neurogenic tumors and congenital cysts are good indications of VATS.
  • Thymic cyst, benign thymic tumor. such as mature teratoma, and small thymoma [noninvasive, diameter less than 5 cm, caudal position from left brachiocephalic vein (LBCV)] are now also indicated to VATS.
  • [MeSH-major] Mediastinal Neoplasms / surgery. Thoracic Surgery, Video-Assisted / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20715448.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


78. Doita M, Miyamoto H, Nishida K, Nabeshima Y, Yoshiya S, Kurosaka M: Giant-cell tumor of the tendon sheath involving the thoracic spine. J Spinal Disord Tech; 2005 Oct;18(5):445-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant-cell tumor of the tendon sheath involving the thoracic spine.
  • Giant-cell tumor of the tendon sheath is a common benign lesion of the synovial membrane that frequently occurs in the hand.
  • It is related to pigmented villonodular synovitis and the occurrence of pigmented villonodular synovitis or giant-cell tumor of the tendon sheath in the axial skeleton is very rare.
  • To data, only three cases of giant-cell tumor of the tendon sheath involving cervical spine have been reported, compared with 26 cases of pigmented villonodular synovitis.
  • Pigmented villonodular synovitis involving the thoracic spine is also extremely rare and our case represents the first reported case of a giant-cell tumor of the tendon sheath involving the thoracic spine.
  • Although giant-cell tumor of the tendon sheath in the thoracic spine may be extremely uncommon, it should be considered in the differential diagnosis, especially when a benign lesion appears to originate in the face joint.
  • [MeSH-major] Giant Cell Tumors / radiography. Giant Cell Tumors / surgery. Soft Tissue Neoplasms / radiography. Soft Tissue Neoplasms / surgery. Tendons. Thoracic Vertebrae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16189458.001).
  • [ISSN] 1536-0652
  • [Journal-full-title] Journal of spinal disorders & techniques
  • [ISO-abbreviation] J Spinal Disord Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Shen R, Ye Y, Chen L, Yan Q, Barsky SH, Gao JX: Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One; 2008;3(2):e1652
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precancerous stem cells can serve as tumor vasculogenic progenitors.
  • Tumor neo-vascularization is critical for tumor growth, invasion and metastasis, which has been considered to be mediated by a mechanism of angiogenesis.
  • However, histopathological studies have suggested that tumor cells might be the progenitor for tumor vasculature.
  • Recently, we have reported that the precancerous stem cells (pCSCs) representing the early stage of developing cancer stem cells (CSCs), have the potential for both benign and malignant differentiation.
  • Therefore, we investigated whether pCSCs serve as progenitors for tumor vasculogenesis.
  • The pCSCs are much more potent in tumor vasculogenesis than the differentiated tumor monocytic cells (TMCs) from the same tumor, which had comparable or even higher capacity to produce some vascular growth factors, suggesting that the potent tumor vasculogenesis of pCSCs is associated with their intrinsic stem-like property.
  • Consistently tumor vasculogenesis was also observed in human cancers such as cervical cancer and breast cancer and xenograft lymphoma.
  • Our studies indicate that pCSCs can serve as tumor vasculogenic stem/progenitor cells (TVPCs), and may explain why anti-angiogenic cancer therapy trials are facing challenge.
  • [MeSH-major] Neoplasms / blood supply. Neovascularization, Pathologic. Precancerous Conditions / pathology. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Nov 1;61(21):8005-13 [11691826.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):721-30 [16077922.001]
  • [Cites] J Clin Invest. 2002 Feb;109(3):337-46 [11827993.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 May;282(5):C947-70 [11940508.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11205-10 [12163646.001]
  • [Cites] Blood. 2003 May 1;101(9):3597-605 [12531805.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):411-21 [12778131.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):5927-35 [12794119.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):133-46 [12957288.001]
  • [Cites] Exp Hematol. 2003 Nov;31(11):987-93 [14585360.001]
  • [Cites] J Appl Physiol (1985). 2005 Sep;99(3):861-6 [15905327.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):2890-9 [16116175.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13156-61 [16920790.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):835-45 [17036040.001]
  • [Cites] Am J Pathol. 2007 Jan;170(1):1-15 [17200177.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):376-83 [17264333.001]
  • [Cites] PLoS One. 2007;2(3):e293 [17356702.001]
  • [Cites] Scand J Immunol. 2007 Apr;65(4):329-35 [17386023.001]
  • [Cites] Genes Dev. 2007 Jun 15;21(12):1546-58 [17575055.001]
  • [Cites] J Cell Mol Med. 2007 May-Jun;11(3):374-82 [17635633.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2085-9 [17878921.001]
  • [Cites] Microvasc Res. 2007 Sep-Nov;74(2-3):72-84 [17560615.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] J Cell Mol Med. 2008 Jan-Feb;12(1):67-96 [18053092.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] Recent Prog Horm Res. 2004;59:51-71 [14749497.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):505-15 [10688871.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1363-80 [10751361.001]
  • [Cites] Blood. 2000 Aug 1;96(3):894-901 [10910902.001]
  • [Cites] Differentiation. 2000 May;65(5):287-300 [10929208.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2818-23 [10946314.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Nature. 2000 Nov 2;408(6808):92-6 [11081514.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14608-13 [11121063.001]
  • [Cites] Semin Thromb Hemost. 2000;26(5):561-9 [11129413.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):273-82 [11169947.001]
  • [Cites] Cell Struct Funct. 2001 Feb;26(1):25-35 [11345501.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jan-Feb;32(1):168-75 [14757432.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):965-9 [15333659.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7164-77 [15378077.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Int J Microcirc Clin Exp. 1985;4(1):31-43 [2580810.001]
  • [Cites] Cell. 1989 May 5;57(3):503-12 [2785856.001]
  • [Cites] Cell. 1993 Mar 26;72(6):835-46 [7681362.001]
  • [Cites] J Neurosci. 1996 Oct 1;16(19):6089-99 [8815891.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Curr Biol. 1998 Apr 23;8(9):529-32 [9560344.001]
  • [Cites] J Exp Med. 1998 Sep 21;188(6):1039-46 [9743522.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] J Immunol. 1999 Aug 15;163(4):2151-9 [10438956.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Immunity. 2004 Dec;21(6):831-42 [15589171.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1076-81 [15644447.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1028-43 [15534359.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] FASEB J. 2002 Feb;16(2):225-7 [11744626.001]
  • (PMID = 18286204.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / Cytokines; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2242848
  •  go-up   go-down


80. Kitahara T, Kondoh K, Kizawa K, Horii A, Kubo T: Two cases of spinal cord extramedullary tumor with positional vertiginous sensation. Acta Otolaryngol Suppl; 2009 Jun;(562):50-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of spinal cord extramedullary tumor with positional vertiginous sensation.
  • Neck-vestibular diseases also induce vertiginous sensation with head and neck movement and need to be ruled out for the diagnosis of benign paroxysmal positional vertigo (BPPV).
  • These cases were finally diagnosed as spinal cord intradural extramedullary tumor (C3-C4) by means of neck MRI.
  • [MeSH-major] Neurilemmoma / diagnosis. Spinal Cord Neoplasms / diagnosis. Vertigo / etiology
  • [MeSH-minor] Aged, 80 and over. Cervical Vertebrae / pathology. Contrast Media. Female. Gadolinium DTPA. Humans. Magnetic Resonance Imaging. Middle Aged

  • MedlinePlus Health Information. consumer health - Dizziness and Vertigo.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19848240.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


86. Arafa M, Boniver J, Delvenne P: Detection of HPV-induced cervical (pre) neoplastic lesions: a tissue microarray (TMA) study. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):422-32
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of HPV-induced cervical (pre) neoplastic lesions: a tissue microarray (TMA) study.
  • The aim of this study was to evaluate the usefulness of a panel of biomarkers in the characterization of human papillomavirus (HPV)-induced cervical lesions.
  • Misinterpretation especially for benign mimics results in a significant diagnostic disagreement.
  • For these reasons, a continuous effort is still needed to discover surrogate markers, which could support the final diagnosis.
  • Archival biopsies of normal ectocervical and endocervical tissues, squamous metaplasia, cervical intraepithelial neoplasia (CIN), squamous cell carcinoma, adenocarcinoma in situ, and adenocarcinoma were retrieved to perform a tissue microarray (TMA).
  • In conclusion, using a panel of cervical biomarkers improves the final reporting of various HPV-induced epithelial lesions.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18542030.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Hajdú N, Zsoldos P, Neuberger G: [Rectum tumor diagnosed by subcutaneous emphysema of the chest]. Magy Seb; 2009 Oct;62(5):308-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rectum tumor diagnosed by subcutaneous emphysema of the chest].
  • BACKGROUND: Various benign and malignant thoracic or abdominal diseases can cause subcutaneous emphysema on the chest, pneumomediastinum or pneumopericardium.
  • METHODS: We report a case of a 72-year-old woman who presented with thoracic and cervical subcutaneous emphysema, pneumomediastinum and pneumopericardium.
  • Further examination revealed that this was caused by a rectal tumor causing large bowel obstruction and a consequent perforation of the transverse colon.
  • CONCLUSIONS: Subcutaneous emphysema of the chest, pneumomediastinum and pneumopericardium are uncommon symptoms and can be a real challenge in diagnosis.
  • [MeSH-major] Colonic Diseases / surgery. Intestinal Obstruction / surgery. Rectal Neoplasms / complications. Rectal Neoplasms / diagnosis. Subcutaneous Emphysema / etiology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Intestinal Perforation / etiology. Mediastinal Emphysema / etiology. Pneumopericardium / etiology. Treatment Outcome


88. He G, Chen L, Ye Y, Xiao Y, Hua K, Jarjoura D, Nakano T, Barsky SH, Shen R, Gao JX: Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16. Am J Transl Res; 2010;2(2):156-69
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16.
  • Generally, cancers may undergo the developmental stages of benign proliferation, precancer and invasive cancer.
  • Piwil2, a member of AGO/PIWI family of proteins, has been suggested to be associated with tumor development.
  • Here we reported that piwil2 can be detected by immunohistochemistry (IHC) in various stages of human cervical squamous cell carcinomas and adenocarcinomas.
  • The results suggest that piwil2 might play important roles throughout the process of cervical cancer development and have the potential to be used as a complementary marker for p16(INK4a).
  • It is worth further study to improve the sensitivity and specificity of current screening methods for cervical cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6626-36 [17121881.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):387-94 [17079091.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13415-20 [16938833.001]
  • [Cites] Genes Dev. 2006 Aug 15;20(16):2214-22 [16882972.001]
  • [Cites] Science. 2006 Jul 21;313(5785):363-7 [16778019.001]
  • [Cites] Nature. 2006 Jul 13;442(7099):203-7 [16751777.001]
  • [Cites] Genes Dev. 2006 Jul 1;20(13):1709-14 [16766680.001]
  • [Cites] Cell. 2006 Jun 2;125(5):873-86 [16751098.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):989-95 [16467114.001]
  • [Cites] Hum Mol Genet. 2006 Jan 15;15(2):201-11 [16377660.001]
  • [Cites] Cancer. 2005 Dec 25;105(6):457-60 [16104044.001]
  • [Cites] Mol Reprod Dev. 2006 Feb;73(2):173-9 [16261612.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):166-72 [15671542.001]
  • [Cites] Cancer Lett. 1999 Feb 8;136(1):101-8 [10211947.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3715-27 [9851978.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] Science. 2004 Sep 3;305(5689):1437-41 [15284456.001]
  • [Cites] BMC Cancer. 2004 Jul 19;4:37 [15257755.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jan;2(1):1-8 [15017625.001]
  • [Cites] Development. 2004 Feb;131(4):839-49 [14736746.001]
  • [Cites] Genomics. 2003 Sep;82(3):323-30 [12906857.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):5927-35 [12794119.001]
  • [Cites] Curr Biol. 2009 Apr 28;19(8):640-4 [19345100.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):210-20 [19261387.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):719-24 [19360079.001]
  • [Cites] PLoS One. 2009;4(2):e4544 [19229342.001]
  • [Cites] J Biol Chem. 2009 Mar 6;284(10):6507-19 [19114715.001]
  • [Cites] Int J Clin Exp Pathol. 2009;2(1):21-33 [18830381.001]
  • [Cites] Trends Mol Med. 2008 Aug;14(8):323-32 [18635398.001]
  • [Cites] J Cell Mol Med. 2008 Jan-Feb;12(1):67-96 [18053092.001]
  • [Cites] PLoS One. 2008;3(2):e1652 [18286204.001]
  • [Cites] Nature. 2007 Nov 8;450(7167):304-8 [17952056.001]
  • [Cites] Lancet. 2007 Sep 8;370(9590):890-907 [17826171.001]
  • [Cites] Science. 2007 May 4;316(5825):744-7 [17446352.001]
  • [Cites] Cell. 2007 Mar 23;128(6):1089-103 [17346786.001]
  • [Cites] Cancer Cell Int. 2007;7:2 [17362521.001]
  • [Cites] MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 [17380109.001]
  • [Cites] PLoS One. 2007;2(3):e293 [17356702.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):295-301 [17301262.001]
  • [Cites] Cancer. 2006 Dec 25;108(6):451-61 [17078096.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2733-42 [12414724.001]
  • [Cites] Oncogene. 2002 Jun 6;21(25):3988-99 [12037681.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] Mech Dev. 2001 Oct;108(1-2):121-33 [11578866.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):311-22 [10653597.001]
  • (PMID = 20407605.001).
  • [ISSN] 1943-8141
  • [Journal-full-title] American journal of translational research
  • [ISO-abbreviation] Am J Transl Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2855633
  • [Keywords] NOTNLM ; Piwil2 / cervical cancer / field cancerization / p16INK4a / precancer / tumor development
  •  go-up   go-down


89. Kohrenhagen N, Voelker HU, Schmidt M, Kapp M, Krockenberger M, Frambach T, Dietl J, Kammerer U: Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res; 2008 Jun;34(3):293-300
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia.
  • AIM: It is supposed that increased glycolysis is crucial for the energy supply during tumor progression.
  • Unfortunately, the relevance of glycolysis in cervical neoplasia is unknown, but what is certain is the fact that cervical cancer shows a high expression of glucose membrane transporters, which are necessary for glucose uptake as an energy source.
  • Thus, we were interested in their expression in cervical tissue.
  • METHODS: We examined the expression of TKTL1 and p-Akt in 80 formalin-fixed, paraffin-embedded cervical specimens: 20 benign cervical tissues, 20 low-grade squamous intraepithelial lesions, 20 high-grade intraepithelial lesions, and 20 invasive squamous cell carcinomas (ISCC).
  • RESULTS: Immunhistochemical analyses revealed that the intensity of the expression of TKTL1 and p-Akt increases significantly with an increase in the histopathological grade of cervical tissues.
  • CONCLUSION: The results suggest that both TKTL1 and p-Akt play an important role in the progression of cervical neoplasia, which may be due to their impact on glycolysis.
  • [MeSH-major] Proto-Oncogene Proteins c-akt / metabolism. Transketolase / metabolism. Uterine Cervical Neoplasms / chemistry
  • [MeSH-minor] Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / chemistry. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / chemistry. Female. Glycolysis. Humans. Immunohistochemistry. Paraffin Embedding

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18686341.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.2.1.1 / TKTL1 protein, human; EC 2.2.1.1 / Transketolase; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


90. Lin G, Ho KC, Wang JJ, Ng KK, Wai YY, Chen YT, Chang CJ, Ng SH, Lai CH, Yen TC: Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J Magn Reson Imaging; 2008 Jul;28(1):128-35
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T.
  • PURPOSE: To evaluate diffusion-weighted imaging (DWI) for detection of pelvic lymph node metastasis in patients with cervical and uterine cancers.
  • RESULTS: The relative ADC values between tumor and nodes were significantly lower in metastatic than in benign nodes (0.06 vs. 0.21 x 10(-3) mm(2)/s, P < 0.001; cutoff value 0.10 x 10(-3) mm(2)/s).
  • CONCLUSION: The combination of size and relative ADC values was useful in detecting pelvic lymph node metastasis in patients with cervical and uterine cancers.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Lymphatic Metastasis. Uterine Cervical Neoplasms / diagnosis. Uterine Neoplasms / diagnosis


91. Xu Q, Wang S, Xi L, Wu S, Chen G, Zhao Y, Wu Y, Ma D: Effects of human papillomavirus type 16 E7 protein on the growth of cervical carcinoma cells and immuno-escape through the TGF-beta1 signaling pathway. Gynecol Oncol; 2006 Apr;101(1):132-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of human papillomavirus type 16 E7 protein on the growth of cervical carcinoma cells and immuno-escape through the TGF-beta1 signaling pathway.
  • In this study, the relationship between HPV-16 infection and the functions of three critical factors of the TGF-beta1/Smads pathway was explored to assess the possible role of E7 in the development of cervical cancer.
  • METHODS: The expression of E7, TGF-beta1, TbetaR-II and Smad4 was detected by immunohistochemistry in paraffin-embedded cervical samples, and by RT-PCR and Western blotting in cervical cancer cell lines.
  • The effect of TGF-beta1 on the growth of cervical cancer cells were tested by methyl thiazolyl tetrazolium (MTT), and the effects of HPV-16 E7 protein on normal and malignant cervical cells were investigated by flow cytometry.
  • RESULTS: During the progression from benign to malignant lesions, the expression levels of TGF-beta1 and Smad4 increased significantly in cervical carcinoma tissues.
  • In vitro experiments showed that TGF-beta1 could not inhibit the proliferation of several cervical carcinoma cell lines in long-term regulation, but could inhibit immunologic reactions of peripheral blood mononuclear cells (PBMCs).
  • CONCLUSIONS: Our data indicate that HPV-16 E7 protein plays an important role during the development of cervical cancer by immuno-inhibition and stimulation of tumor cell proliferation through the TGF-beta1/Smads signaling pathway.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / metabolism. Human papillomavirus 16 / metabolism. Oncogene Proteins, Viral / biosynthesis. Papillomavirus Infections / metabolism. Transforming Growth Factor beta / biosynthesis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Cell Growth Processes. Cell Line, Tumor. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Enzyme-Linked Immunosorbent Assay. Female. HeLa Cells. Humans. Interferon-gamma / secretion. Interleukin-2 / secretion. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / secretion. Oligonucleotides, Antisense / genetics. Papillomavirus E7 Proteins. Protein-Serine-Threonine Kinases. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Transforming Growth Factor beta / biosynthesis. Signal Transduction. Smad4 Protein / biosynthesis. Transfection. Transforming Growth Factor beta1

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269171.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Oligonucleotides, Antisense; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / RNA, Messenger; 0 / Receptors, Transforming Growth Factor beta; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 0 / oncogene protein E7, Human papillomavirus type 16; 82115-62-6 / Interferon-gamma; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


92. Bhosale P, Peungjesada S, Devine C, Balachandran A, Iyer R: Role of magnetic resonance imaging as an adjunct to clinical staging in cervical carcinoma. J Comput Assist Tomogr; 2010 Nov-Dec;34(6):855-64
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of magnetic resonance imaging as an adjunct to clinical staging in cervical carcinoma.
  • Magnetic resonance imaging depicts the morphological details of the female pelvis and is useful for evaluating both benign and malignant cervical masses.
  • Clinical assessment of the extent of cervical cancer is crucial in determining the optimal treatment strategy, but clinical staging by itself has limitations.
  • The prognosis of cervical cancer is determined not only by stage, but also by nodal status, tumor volume, and depth of invasion, none of which are included in the FIGO guidelines.
  • Magnetic resonance imaging has been described as the most accurate, noninvasive imaging modality in staging cervical carcinoma.
  • This review outlines the magnetic resonance features of normal cervix, primary disease (by stage), and recurrent disease and discusses the role of magnetic resonance imaging in staging and clinical decision making.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Contrast Media. Female. Humans. Lymphatic Metastasis / pathology. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084900.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


93. Fukunari F, Okamura K, Zeze R, Kagawa T, Hashimoto K, Yuasa K: Cervical lymph nodes with or without metastases from oral squamous carcinoma: a correlation of MRI findings and histopathologic architecture. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jun;109(6):890-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical lymph nodes with or without metastases from oral squamous carcinoma: a correlation of MRI findings and histopathologic architecture.
  • STUDY DESIGN: The signal intensities of 98 cervical lymph nodes from 20 patients with oral squamous cell carcinoma were evaluated on T2-weighted and diffusion-weighted whole-body imaging with background body signal suppression (DWIBS).
  • Using DWIBS images with inverted black-and-white image contrast, cystic degeneration, keratinization, fibrous tissue, tumor tissue, and lymphoid tissue were either hypointense or intermediate in intensity.
  • Using DWIBS images, it was difficult to differentiate metastatic from benign lymph nodes.
  • [MeSH-major] Lymph Nodes / radiography. Lymphatic Metastasis / radiography. Magnetic Resonance Imaging. Mouth Neoplasms / pathology. Neoplasms, Squamous Cell / radiography

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20299250.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


94. Zätterström U, Thor A, Nordgren H: Cervical metastasis from Spitz nevus of the buccal mucosa. Melanoma Res; 2008 Feb;18(1):36-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical metastasis from Spitz nevus of the buccal mucosa.
  • Cytology from fine needle aspiration indicated spread of a melanocytic tumor and she underwent a modified supraomohyiod neck dissection.
  • It is believed that this may be an example of how a Spitz tumor, although inherently benign, can spread along lymphatics in a pseudometastatic fashion.
  • [MeSH-major] Head and Neck Neoplasms / secondary. Mouth Mucosa / pathology. Mouth Neoplasms / pathology. Nevus, Epithelioid and Spindle Cell / pathology

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Spitz nevus.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18227706.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Poliani PL, Sperli D, Valentini S, Armentano A, Bercich L, Bonetti MF, Corriero G, Brisigotti M, Quattrone A, Lanza PL: Spinal glioneuronal tumor with neuropil-like islands and meningeal dissemination: histopathological and radiological study of a pediatric case. Neuropathology; 2009 Oct;29(5):574-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal glioneuronal tumor with neuropil-like islands and meningeal dissemination: histopathological and radiological study of a pediatric case.
  • Cerebral and spinal location of glioneuronal tumors have been recently described as a novel type of primary CNS neoplasia.
  • In the present report we describe a case of a 15-month-old child with a spinal GTNI of the cervical region and meningeal dissemination.
  • Histologically the tumor was composed of round, small neurocytic-like cells arranged around eosinophilic neuropil cores and embedded in a diffuse fibrillar glial component forming prominent "rosetted" neuropil islands displaying strong immunoreactivity for neuronal markers.
  • Nevertheless, due to their exceptional rarity, the natural history of these lesions is not yet fully understood, but spinal GTNI seems to have an unfavorable clinical course despite their benign histopathological features, which must be taken into account for appropriate treatment and follow-up of the patient.
  • [MeSH-major] Brain Neoplasms / secondary. Meningeal Neoplasms / secondary. Neoplasms, Nerve Tissue / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Cervical Vertebrae. Fatal Outcome. Humans. Infant. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077041.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


96. Ungureanu C, Teleman S, Socolov D, Anton G, Mihailovici MS: [Evaluation of p16INK4a and Ki-67 proteins expression in cervical intraepithelial neoplasia and their correlation with HPV-HR infection]. Rev Med Chir Soc Med Nat Iasi; 2010 Jul-Sep;114(3):823-8
MedlinePlus Health Information. consumer health - HPV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of p16INK4a and Ki-67 proteins expression in cervical intraepithelial neoplasia and their correlation with HPV-HR infection].
  • OBJECTIVE: The aim of our study was to evaluate the expression of p16INK4A and Ki-67 in cervical intraepithelial neoplasia (CIN) and to correlate the high-risk human papillomavirus (HPV) infection with these two biomarkers.
  • RESULTS: 7 of our cases were benign (11.66%); 18 cases presented CIN1 (30%), 14 cases CIN2 (23.33%), 16 cases CIN3 (26.66%) and 5 cases invasive squamous cell carcinoma (8.33%).
  • Therefore, in the diagnosis of CIN and high-risk HPV infection, p16INK4A can be a useful biomarker.
  • [MeSH-major] Alphapapillomavirus / isolation & purification. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ki-67 Antigen / metabolism. Papillomavirus Infections / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21243810.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen
  •  go-up   go-down


97. Araujo Júnior E, Guimarães Filho HA, Saito M, Pires AB, Pontes AL, Nardozza LM, Moron AF: Prenatal diagnosis of a large fetal cervical teratoma by three-dimensional ultrasonography: a case report. Arch Gynecol Obstet; 2007 Feb;275(2):141-4
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prenatal diagnosis of a large fetal cervical teratoma by three-dimensional ultrasonography: a case report.
  • CONTEXT: The cervical teratomas are rare, benign tumors, they are formed by the three embryonic layers, and they represent only 6% of teratomas.
  • The prognosis depends mainly on the size and location of the lesion, on the tumor growth rate, and on the level of tracheal compression.
  • Prenatal diagnosis is usually reached with the aid of a two-dimensional ultrasonography (2DUS) after the 15th week of gestation, which shows a large heterogeneous mass in the cervical region, plus a polyhydramnios, on the Doppler mode which also shows the vascularization of the tumor.
  • CASE REPORT: We report a case of cervical teratoma diagnosed on the 31st week of gestation with the aid of a 2DUS and color Doppler mode.
  • [MeSH-major] Fetal Diseases / ultrasonography. Head and Neck Neoplasms / ultrasonography. Imaging, Three-Dimensional / methods. Teratoma / ultrasonography. Ultrasonography, Prenatal / methods

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770588.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


98. Schledermann D, Andersen BT, Bisgaard K, Dohse M, Ejersbo D, Hoelund B, Horal P, Lindh M, Ryd W: Are adjunctive markers useful in routine cervical cancer screening? Application of p16(INK4a) and HPV-PCR on ThinPrep samples with histological follow-up. Diagn Cytopathol; 2008 Jul;36(7):453-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are adjunctive markers useful in routine cervical cancer screening? Application of p16(INK4a) and HPV-PCR on ThinPrep samples with histological follow-up.
  • The objectives of the study were to evaluate 1) the diagnostic sensitivity and specificity of p16(INK4a) as a marker for high-grade cervical lesions, 2) the results of a real-time polymerase chain reaction detecting high-risk human papillomavirus, and 3) the interobserver variability of the p16(INK4a) interpretation.A total of 232 ThinPrep samples were stained for p16(INK4a), and HPV-DNA PCR was performed on 107 specimens with inclusion of both benign and abnormal cytology.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervical Intraepithelial Neoplasia / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Immunohistochemistry. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cervix Uteri / chemistry. Cervix Uteri / virology. DNA, Viral / analysis. Female. Histological Techniques. Humans. Middle Aged. Observer Variation. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18528890.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  •  go-up   go-down


99. Rodrigues LM, Nicolau RJ, Puertas EB, Milani C: Vertebrectomy of giant cell tumor with vertebral artery embolization: case report. J Pediatr Orthop B; 2009 Mar;18(2):99-102
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vertebrectomy of giant cell tumor with vertebral artery embolization: case report.
  • Giant cell tumors (GCT) are rare in the cervical spine in adolescent children.
  • This tumor is histologically benign, but there is a high recurrence rate.
  • Although surgical resection of GCT arising in the cervical spine is commonly regarded as recommended treatment method, it is still a challenge to achieve satisfactory results.
  • The authors describe a case of a patient of adolescent age with a GCT in the cervical spine.
  • It was necessary to study the embolization of the vertebral artery to planning the vertebrectomy surgery for resection of the entire tumor to avoid recurrence.
  • The resection of the tumor was carried out by combined access (anteriorly and posteriorly) and was stabilized with plate, posterior lateral mass screws, and autologous iliac crest graft.
  • [MeSH-major] Cervical Vertebrae / surgery. Embolization, Therapeutic / methods. Giant Cell Tumor of Bone / therapy. Spinal Neoplasms / therapy. Vertebral Artery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276993.001).
  • [ISSN] 1473-5865
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Shi J, Liu H, Wilkerson M, Huang Y, Meschter S, Dupree W, Schuerch C, Lin F: Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions. Hum Pathol; 2007 Sep;38(9):1335-44
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions.
  • We immunohistochemically evaluated the diagnostic value of p16, MCM2, TOP IIA, ProE(X) C, and a cocktail of p16 and ProE(X) C in 62 cervical biopsy specimens, including 14 cases of benign squamous mucosa (group 1), 34 cases of LSILs (group 2), and 14 cases of HSILs (group 3).
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / pathology. Cell Cycle Proteins / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA Topoisomerases, Type II / analysis. DNA-Binding Proteins / analysis. Nuclear Proteins / analysis. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2009 Jun;40(6):904-5; author reply 905-6 [19442790.001]
  • (PMID = 17512033.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down






Advertisement